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Integrated Multimodal Genomic Analyses Reveal Novel Mechanisms of
Glucocorticoid Resistance in Acute Lymphoblastic Leukemia
Abstract
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Much has been discovered in
recent decades regarding ALL biology, and the outcome of patients with ALL has vastly improved,
especially in pediatric ALL patients. Despite very promising overall cure rates, patients who relapse have a
greatly decreased prognosis with survival rates ranging from 30-60%. These numbers stand to improve
even further with new targeted therapies that seek to improve or maintain cure rates while reducing
treatment related toxicities which affect patients both acutely and chronically. Glucocorticoids (GCs) are
essential components of modern chemotherapeutic intervention for ALL. Resistance to glucocorticoids is
an important factor in determining early treatment response and overall patient survival. Reduction of
glucocorticoid induced toxicities, such as osteonecrosis, can significantly affect patient quality of life and
are associated with high dose glucocorticoid treatment in pediatric patients. Both endogenous and
exogenous glucocorticoids exert their mechanism of action through various pleiotropic effects that
regulate numerous cellular functions and can cause selective cytotoxicity in lymphoid malignancies. The
complex mechanism of action of glucocorticoids is evident in the number of diverse clinically relevant
molecular pathways that have been previously associated with resistance to glucocorticoids in ALL.The
identification of genomic and epigenomic mechanisms of glucocorticoid resistance are important for
improving ALL treatment outcomes. We used an agnostic genome-wide method to interrogate multiple
types of genomic information (mRNA and miRNA expression, DNA methylation, SNPs, CNAs and SNVs/
Indels) in primary human acute lymphoblastic leuke
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ABSTRACT
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer.
Much has been discovered in recent decades regarding ALL biology, and the outcome of
patients with ALL has vastly improved, especially in pediatric ALL patients. Despite
very promising overall cure rates, patients who relapse have a greatly decreased
prognosis with survival rates ranging from 30-60%. These numbers stand to improve
even further with new targeted therapies that seek to improve or maintain cure rates while
reducing treatment related toxicities which affect patients both acutely and chronically.
Glucocorticoids (GCs) are essential components of modern chemotherapeutic
intervention for ALL. Resistance to glucocorticoids is an important factor in determining
early treatment response and overall patient survival. Reduction of glucocorticoid
induced toxicities, such as osteonecrosis, can significantly affect patient quality of life
and are associated with high dose glucocorticoid treatment in pediatric patients. Both
endogenous and exogenous glucocorticoids exert their mechanism of action through
various pleiotropic effects that regulate numerous cellular functions and can cause
selective cytotoxicity in lymphoid malignancies. The complex mechanism of action of
glucocorticoids is evident in the number of diverse clinically relevant molecular
pathways that have been previously associated with resistance to glucocorticoids in ALL.
The identification of genomic and epigenomic mechanisms of glucocorticoid
resistance are important for improving ALL treatment outcomes. We used an agnostic
genome-wide method to interrogate multiple types of genomic information (mRNA and
miRNA expression, DNA methylation, SNPs, CNAs and SNVs/Indels) in primary human
acute lymphoblastic leukemia cells. We identified 463 genomic features associated with
glucocorticoid resistance. Gene-level aggregation by a novel statistical method (TAP)
identified 118 overlapping genes, 15 of which were confirmed by genome-wide CRISPR
screening. Upon review of known glucocorticoid resistance mechanisms, we directly
identified 30 of 38 (79%) genes/miRNAs and all 38 known resistance pathways,
revealing 14 of 15 of our top candidate genes were not previously associated with
glucocorticoid-resistance. CELSR2, the top novel gene downregulated in glucocorticoid
resistant ALL was corroborated by single cell RNAseq and network-based transcriptomic
modeling (NetBID). shRNA knockdown of CELSR2 recapitulated glucocorticoid
resistance in human leukemia cell lines and revealed a synergistic drug combination
(prednisolone and venetoclax), based on high BCL-2 expression, that was able to mitigate
glucocorticoid resistance in mouse xenografts.
In summation, we illustrated the power of a multi-dimensional integrative
genomic strategy for elucidating genes and pathways conferring glucocorticoid resistance
in patients with ALL. These findings will provide important new targets for treating
glucocorticoid resistant ALL.
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CHAPTER 1.

INTRODUCTION

Acute Lymphoblastic Leukemia (ALL)
Acute lymphoblastic leukemia (ALL) is a malignant neoplasm composed of
immature white blood cells known as lymphoblasts which can accumulate in the
peripheral blood, bone marrow and other organs causing tissue damage and inhibiting
normal hematopoietic cell development. The most common presenting features of
childhood ALL (occurring in more than 50% of cases) at or prior to diagnosis are
hepatomegaly, splenomegaly, pallor, fever and bruising.1 Immunophenotype lineage
determination by flow cytometric analysis of extracellular surface markers can classify
the leukemia as either the more common B-lineage ALL (85% of cases) or T-lineage
ALL.2
Prevalence
ALL is the most prevalent type of cancer in children accounting for 25% of all
childhood cancer diagnoses with an estimated 3,000 cases per year in children from ages
1-19 (peaking in incidence from ages 2-4 in industrialized countries). Notably, there has
been an upward trend in pediatric ALL incidence over the past 40 years.3,4 Recent studies
have proposed that early exposure to infections (i.e. infant day care attendance) may
provide protection from childhood ALL.5,6
Molecular Subtypes of ALL
The majority of B-ALL (approximately 75%) exhibit aneuploidy or have
recurring large chromosomal rearrangements that have been shown to be important in
leukemogenesis,7,8 but these are unable to fully explain the complex biology of the
disease.9 Until the last decade, ALL was described by either aneuploidy resulting in large
chromosomal gains (hyperdiploidy) or losses (hypodiploidy) or by four more commonly
observed translocations including 25% of patients with t(12;21) [ETV6–RUNX1],5% of
patients with t(1;19) [TCF3–PBX1], 3% of patients having t(9;11) [BCR–ABL1] and 5%
of patients who have MLL gene translocations.
These genetic changes have important prognostic significance. For example,
ETV6-RUNX1 ALL has a favorable prognosis (97.6% vs 83% 5-year EFS).10 Conversely,
BCR-ABL1-translocation is a high-risk feature but has been more successfully treated
recently since the inclusion of targeted tyrosine kinase inhibitors into clinical protocols.11
Genome-wide DNA and RNA sequencing has identified many submicroscopic alterations
that may help define new molecular subtypes of ALL, Also, there are alterations seen in
many protooncogenes (Ras pathway), tumor-suppressors (e.g. CDKN2A/B) and B-cell
developmental genes (PAX512 and IKZF113) which in the case of PAX5 have led to the
discovery of new distinct molecular subtypes of ALL (PAX5 P80R and PAX5alt) that
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bring the current total to 23 unique molecular subtypes of B-ALL.14 Even with the
exceptional advances in understanding the genomic landscape of ALL, the precise
mechanisms underlying the pathogenesis of ALL are not fully understood, and further
study is required to derive the initiating genetic lesions in many cases.
Germline Variation Involved in ALL Development
In contrast to studies looking at acquired somatic variants, the host genome and
inherited germline polymorphisms have arisen as important factors susceptibility of
individuals to develop childhood ALL and have been found to also affect the severity of
the resulting disease. It was discovered that there is a link between germline mutations in
the tumor suppressor TP53 that are known to cause Li-Fraumeni Syndrome and an
increased incidence of hypodiploid ALL in affected patients.15 Also, recurrent inherited
heterozygous germline mutations within the octapeptide domain of the PAX5 gene were
discovered by studying two unrelated families and were highly associated with ALL
occurrence in these patients.16 Genome-wide association studies (GWAS) identified
germline variants in genes associated with increased risk of ALL occurrence ARID5B,
IKZF1, CEBPE, ETV6,CDKN2A and PIP4K2A-BMI1.17-19 Also, GATA3 SNPs were
associated with increased incidence of Ph-like ALL and increased risk of relapse which
served as an example that inherited variants can cause development of specific subtypes
of ALL.20
Refinement of ALL Therapy and Improved Outcomes
Over the last 50 years, there have been exceptional gains in the prognostic outlook
for pediatric ALL. From the inception of St. Jude Children’s Research Hospital in 1962,
the cure rate for ALL was less than 10% and it has now increased to greater than 90%.21
Recently, similar cure rates have been achieved in nationwide multi-center protocols with
the most recently completed Children’s Oncology Group study AALL0331 reporting an
89% 6 year event-free survival (EFS) and 95.5% overall survival rate in children with
newly diagnosed standard risk (SR) ALL.22 These improvements can be attributed to a
number of important advances. Initially, multi-agent chemotherapy regimens with longer
duration, methods to reduce secondary infection and reduction in CNS involvement by
targeted therapy provided the first wave of improvement in patient outcomes. More
recently, refinements in treatment protocols have been derived from an increased
understanding of the biological heterogeneity of ALL and the ability to monitor minimal
residual disease (MRD)23,24 which has allowed for refinement of protocols to stratify
patients based on risk of relapse to greatly maximize cure rates while reducing toxicity.
Despite the vast improvements in treatment outcome, ALL remains a leading cause of
childhood cancer-related death. Relapsed ALL though occurring at a much lower rate has
a very poor prognosis with an overall survival rate of 30-60%.25-28 Assessment of drug
resistance shows that leukemia blasts are more resistant to a variety of agents at relapse
than at diagnosis and both de novo and acquired resistance are thought to be key
determinants of relapse in ALL.29,30 Great efforts have been made to discover ways to
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prevent drug resistance in ALL in hopes of decreasing the occurrence of toxicity caused
by conventional chemotherapy while maintaining or improving treatment outcomes.
Glucocorticoid Mechanism of Action
The glucocorticoid receptor (GR) is a member of the steroid hormone receptor
family of nuclear receptors. It functions as the receptor for the endogenous glucocorticoid
cortisol. The function of endogenous glucocorticoids is to minimize inflammatory
response through control of the Hypothalamic-Pituitary-Adrenal Axis.31 Synthetic
glucocorticoids (e.g. dexamethasone and prednisone/prednisolone) can also bind the GR
with high affinity and have been used therapeutically to treat inflammatory conditions
such as rheumatoid arthritis.32 The inactive glucocorticoid receptor is bound in the
cytosol by chaperones heat shock proteins HSP70 and HSP90 and co-chaperones (e.g.
FKBP52). Glucocorticoids enter the cell and bind to the inactive glucocorticoid receptor
and cause it to dissociate from its chaperone proteins.33 The unbound glucocorticoid
receptor is then translocated to the nucleus and can homodimerize with other
glucocorticoid receptor monomers while binding to DNA at glucocorticoid response
elements (GREs) to induce gene transcription (transactivation) or repress gene expression
either directly or indirectly (transrepression). Binding site availability may vary based on
tissue-specific chromatin accessibility.
Positive Glucocorticoid Receptor Functions
The most commonly accepted mechanism of transactivation suggests that the GR
dimerization causes a conformational change in the GR and then it recruits co-factors like
histone acetyl transferases (HATs) leading to proximal opening of the chromatin to
facilitate gene expression. It has recently been observed that monomeric GR binding at
“half-sites” can occur and drive transcription through transactivation and at negative
GRE sites (nGREs)34 to repress gene expression in the same manner. It has been shown
that exogenous GCs favor homodimeric GR mechanism and disrupt these “halfsites”.35,36
Negative Glucocorticoid Receptor Functions
The GR can exert negative effects on gene expression by a number of
mechanisms. One important mechanism of direct transrepression is through proteinprotein interactions known as “tethering” where monomeric GR cross-talks with another
transcription factor (TF). This can also be seen in the context of transactivation in some
cases involving assistance from co-factors. Selection of binding partners is a precise
mechanism based on the specific DNA binding sequence.37,38 Both monomeric and
dimeric GR can also compete for overlapping binding sites to act as a repressor by
blocking binding of other transcription factors. It has been recently discovered that both
inverted repeat nGREs exist to which agonist bound GR can bind two monomers with
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reverse polarity to repress expression,34 in some cases the GRβ isoform can compete for
active GRα binding sites and repress expression of target genes.39
Non-genomic Glucocorticoid Receptor Functions
There are also other factors that can affect the mechanisms of action of the
glucorticoid receptor such as post-translational modifications (phosphorylation,
acetylation, ubiquitination, methylation, nitrosylation and SUMOylation) that can
regulate a wide array of GR functions. It has been observed previously that there are
glucocorticoid induced effects that occur very rapidly (seconds to minutes) which belies
the fact that there must be non-genomic GR mechanisms, most of which are thought to be
initiated in the cytoplasm.40 These mechanisms also include membrane bound GR which
has distinct signaling functions41,42 and the ability of the GR to regulate transcription of
mitochondrially expressed genes the trafficking of which may be mediated by a Bag-1
mediated BCL2/GR protein complex that can translocate into the mitochondria and effect
function.43-46
In summary, the glucocorticoid receptor has a number of complex and diverse
functions and regulatory mechanisms which can be highly tissue specific and provide a
variety of signals to the cell.
Glucocorticoid Treatment in ALL
Glucocorticoids have been essential components of curative chemotherapy
regimens for many decades, and response to this class of drugs remains pivotal in
determining early treatment response and treatment outcome.47 Glucocorticoids exhibit
cell type specific cytotoxicity in lymphoid malignancies and cause cells to inhibit
cytokine production, undergo cell cycle arrest and apoptosis. Initially, prednisolone was
the most commonly used glucocorticoid in ALL therapy, but dexamethasone use has
increased in recent years because of reports that it is better able to prevent CNS
infiltration, has a longer half-life and ability penetrate the CNS. However, prednisolone
has shown in a number of studies to be associated with lower incidence of an important
dose limiting toxicity of glucocorticoid treatment which is osteonecrosis.33 Ex vivo
prednisolone response profiling of primary leukemia cells to glucocorticoids was shown
to be highly correlated with patient response to therapy and treatment outcome.48,49
Introduction to Pharmacogenomics
Pharmacogenomics is the study of the role of genetics as it relates to drug
response essentially combining the two fields of genomics and pharmacology. Response
to drug therapy can vary greatly in a population and adverse drug responses (ADRs) are a
leading cause of patient mortality in hospitals.50 Some patients may have genetic
characteristics that make them highly susceptible (sensitive) to drug therapy where they
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may need a lower dose of a drug than an average patient and could be at risk to develop
adverse drug reactions within a normal dose range. Other patients may be poorly
responsive to the drug (resistant), meaning it takes a larger dose to achieve desired
therapeutic outcome. Depending on the drug being administered and its therapeutic
window there may be dose limiting toxicities at higher concentrations of the drug.51,52
Pharmacogenomic mechanisms can be pharmacokinetic in nature involving
difference in drug absorption, distribution, metabolism or excretion (ADME) or
pharmacodynamic in nature involving the effects of the drug on the body. Application of
pharmacogenomic techniques in pediatric ALL and other diseases provides new avenues
to discover therapeutic targets to reduce resistance and toxicity and have shown
promising results in prior studies.53 Anticancer agents provide particularly challenging
pharmacogenomic questions because of their narrow therapeutic index which factors in
determining the clinical actionability of a variant when implementing pharmacogenomics
in the clinical setting.54
Hypothesis and Specific Aims
Previous research by our group and other groups has shown that glucocorticoid
resistance in ALL is defined by a diverse array of genetic changes that can be defined by
alterations in important cellular processes that are in many cases involved in the
downstream pleiotropic effects of glucocorticoid treatment. Though many studies have
looked at glucocorticoid resistance in childhood ALL, relevant clinical strategies have not
been developed or implemented to combat this very important challenge. Key
mechanisms and actionable targets that are significant in large scale genome-wide
clinical genomic studies remain widely undiscovered due in part to the lack of
prioritization by large-scale in vitro functional candidate gene validation.
We hypothesize that an integrated polygenomic interrogation of primary ALL
cells coupled with agnostic genome-wide CRISPR/Cas9 screening of glucocorticoids in
leukemia cell lines will identify novel genomic/epigenomic alterations involved in
previously undiscovered regulatory mechanisms of glucocorticoid resistance in ALL. To
validate our hypothesis we propose the following specific aims.
Aim 1: Genome-Wide CRISPR/Cas9 Knockout Screening
To use genome wide CRISPR/Cas9 knockout screens to identify genes in human
acute lymphoblastic leukemia (ALL) cell lines that increase resistance to glucocorticoids.
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Aim 2: Integrated Polygenomic Analyses of Glucocorticoid Resistance in Patient
ALL
To determine whether variants in genes identified in genome wide CRISPR/Cas9
screens of ALL cell lines are also associated with glucocorticoid resistance genes in
primary leukemia cells from newly diagnosed ALL patients (de novo resistance).
Aim 3: Functional Mechanisms of Candidate Resistance Genes
To recapitulate drug resistant phenotypes in human ALL cell lines and/or patient
derived xenografts by manipulating the expression of candidate genes, as a strategy to
better understand biological pathways that are perturbed by genomic variants associated
with glucocorticoid resistance.
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CHAPTER 2.

THE HALLMARKS OF GLUCOCORTICOID RESISTANT ALL
De Novo versus Acquired Resistance

Currently, there are two main proposed mechanisms for how drug resistance
occurs in cancer cells. De novo (intrinsic) resistance which postulates that mutations or
other genomic changes are harbored at initial diagnosis either through somatic change,
inherited variance or other phenomenon that may not be directly involved in the
acquisition of the cancer phenotype or the malignancy of disease. This theory relies on
the heterogeneity of cancer at diagnosis and the fact that the genetic alteration must
provide selective advantage for the cells to resist death from drug treatment even if only a
small subset of the initial population harbors a selective advantage and persist. Acquired
resistance mechanisms are described as new genetic alterations leading to drug resistance
in cells that are not present at initial diagnosis but acquired either by new mutations that
arise by DNA damage from conventional cytotoxic therapies or other activation of
secondary lesions not found at diagnosis.55,56 Proper resolution to determine whether
these are truly acquired lesions caused by drug-induced DNA damage and that they are
not present at a low frequency initially (undetectable in bulk sequencing) is lacking.
Recent studies in single cell sequencing have shown that low frequency mutations not
seen in bulk sequencing may account for some of the unobserved mutations that appear at
relapse and that these methods may allow for determination of mutation acquisition
order.57
Multidimensional Modalities of Drug Resistance
There are many potential ways that drug resistance can arise in ALL. There are
three main categories that we will use to describe the landscape of glucocorticoid
resistance in ALL in this chapter Figure 2-1.
Genomic Determinants
Genomic determinants of drug resistance could be somatic coding or non-coding
mutations, copy number variants, germline polymorphisms or other direct changes to the
DNA sequence of either the cancer cells or the patient’s germline that cause the patient to
be resistant to drug therapy. Another potential genomic determinant could be changes in
the mRNA expression that cause the cancer cells to be resistant which could be regulated
by a variety of external factors.
Epigenomic Determinants
Resistance can also arise from changes in epigenetic factors such as DNA
methylation which can directly affect gene expression. Also, changes in chromatin
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Figure 2-1. Modalities of drug resistance
Drug resistance can be caused by a diverse array of mechanisms. At the genomic level,
there can be mutations or copy number alterations. In some cases, epigenomic changes
such as DNA methylation or chromatin structural changes can cause resistance. Also,
non-genomic factors such as miRNAs, protein-protein interactions post-translational
modifications or other external mechanisms can lead to the drug resistant phenotype.
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accessibility due to altered expression or function of SWI/SNF complex components or
the histone marks that determine the heterochromatin state of the DNA are known to have
important functional roles in the regulation of gene expression and could provide global
phenotypic changes when altered especially in the context of resistance.
Non-genomic Mechanisms
Non-genomic mechanisms also are likely to play a role in drug resistance.
miRNAs can act both post-transcriptionally and post-translationally to affect the
expression of genes and functions of proteins and can cause glucocorticoid resistance if
they are dysregulated. Changes in cell metabolism are another avenue of resistance
especially to glucocorticoids which exert some of their cytotoxic effect by altering
glucose metabolism. There could also be changes in drug metabolizing enzymes or
transporters that alter the amount of available drug able to reach its target and lead to
resistance. Also, changes that affect proteins directly such as posttranslational
modifications that lead to increased turnover or decreased stability may be another path
to resistance.
Hallmark Pathways of Glucocorticoid Resistant ALL
In this section we will discuss the many diverse pathways that have been
identified previously to be associated with glucocorticoid resistance in ALL.
Glucocorticoid Receptor and Co-Factors
GR Expression
For over 35 years, it has been known that decreased glucocorticoid receptor
expression impacts the prognosis for childhood acute lymphoblastic leukemia. Pui, et. al
described that across a number of pediatric ALL cohorts low GR expression was
associated with both induction failure and more frequent relapse, but when high-risk and
standard risk were evaluated separately this was no longer related to outcome suggesting
that it is directly related to the treatment efficacy and was not an independent factor.58
GR Mutation
There has been some evidence linking glucocorticoid resistance in ALL to
somatic glucocorticoid receptor mutations. Initial studies reported that alternative first
exons of the GR could affect the response of leukemic cell lines to glucocorticoids.59
There have been subsequent reports that somatic mutations were not detected in
glucocorticoid resistant patients,60 but in larger cohorts a number of deletions and
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inactivating mutations have been identified that can lead to loss of GR function and
increased relapse risk.12,61 In relapsed ETV6-RUNX1 ALL, mutations in NR3C1 were
acquired through treatment, but it was not explored whether these may have existed at an
undetectable frequency at diagnosis.62 Since GR mutations are rare, they cannot
adequately account for the observed frequency of glucocorticoid resistance. Thus, it is
likely that genes upstream or downstream of the GR must be involved in mediating
glucocorticoid resistance.
GR Degradation
Altering the degradation rate of the glucocorticoid receptor has significant effects
on the ability of cells to respond to glucocorticoid receptor activation by the addition of
exogenous glucocorticoids in ALL and other models. Loss of function of the E3 ubiquitin
ligase FBXW7 was associated with good prognosis and early glucocorticoid treatment
response in childhood T-ALL.63 This specific degradation event is mediated by glycogen
synthase kinase 3β (GSK3B) phosphorylation of GRα at serine 404 (S404) leading to its
subsequent ubiquitination and proteasomal degradation.64
Co-Factors
NCOR1 (nuclear receptor corepressor 1) mutations were previously associated
with relapse in ALL.65 Also, higher expression of multiple HDAC family members
(HDAC3, HDAC4, HDAC7 and HDAC9) which are also NCOR complex components
were associated with poor prognosis. NCOR complex plays a role in disease outcome in
ALL,66,67 likely through its relationship to glucocorticoid response. This is further
evidenced by recurrent deletions, mutations and decreased expression in relapsed ALL of
the transcription factor TBLXR1 which is a member of the NCOR complex.68 TBL1XR1 is
involved in the degradation of NCOR and this is essential for gene activation by a
number of nuclear receptors.69,70
Another transcriptional co-activator that has been implicated in glucocorticoid
resistance is the cAMP responsive element binding protein (CREB) binding protein
(CREBBP). Initially, it was observed that 18.3% of relapsed ALL cases had sequence or
deletion mutations in CREBBP.65 CREBBP (CBP) functions as a histone acetyltransferase
and can act as a scaffold for other proteins in the transcriptional complex.71 CBP can
directly affect glucocorticoid responsive elements and that in some cases CREBBP is
altered in resistant leukemia cell lines.65,72,73 In one study, it was found that CREBBP
knockdown by shRNA was insufficient to cause glucocorticoid resistance in the 697
leukemia cell line.74
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Inflammasome Activation
NALP3 inflammasome pathway components NLRP3 and CASP1 were
overexpressed in glucocorticoid resistant B and T-lineage ALL. This was observed at the
mRNA level, and often coincided with decreased promoter methylation at NLRP3 or
CASP1. It was further observed that overexpressing CASP1 in inflammasome activated
leukemia cell lines resulted in significantly increased cleavage of the GR. This caused
functional loss GR activity and decreased sensitivity to glucocorticoid induced cell death
providing a functional mechanism derived from the initial clinical findings.75
TXNIP (thioredoxin interacting protein) is required for NLRP3 inflammasome
activation in presence of high glucose induced oxidative stress.76 It also functions as a
glucose feedback sensor which was confirmed via CRISPR/Cas9 knockout of TXNIP that
showed a similar change in glucose transport to NR3C1 CRISPR knockout in the same
patient derived cells. It was associated with glucocorticoid resistance in PDX models
when knocked down and agonists for this protein synergized with glucocorticoids. TXNIP
is regulated by PAX5 and IKZF1 which are critical B-cell developmental factors,77 and is
known to be upregulated in leukemia cells when cells are treated with glucocorticoids.78
TXNIP potentially provides a link between the inflammatory and the metabolic changes
observed from glucocorticoid treatment and may lead to potential therapeutic targets in
combatting glucocorticoid resistant ALL.
Glycolytic Pathway
Regulation of glucose homeostasis is important for modulating prednisolone
resistance. It was shown that prednisolone resistant ALL relies on increased glucose
consumption and that inhibition of glycolysis sensitized prednisolone-resistant ALL cell
lines to glucocorticoids.79 This suggests that at least some of the cytotoxicity of
glucocorticoids in ALL can be attributed to their ability to negatively affect glucose
uptake. Cells that can evade this glucose repressive effect may rely heavily on glycolysis
which is an inefficient process for energy production and is achieved by upregulating
genes such as GAPDH or other glycolytic components.80 Cells that can switch to
glycolysis readily are able to resist treatment with glucocorticoids.
Cytokine Signaling
Another mechanism of glucocorticoid resistance occurs when leukemia cells can
alter expression and signaling in response to cytokines or other exogenous signals which
can lead to large scale cellular changes both within the cell and externally. Interaction
with the bone marrow microenvironment via stromal cells or normal T-cells can greatly
influence the response of leukemia cells to drugs. It has been previously illustrated that
combined treatment with IL-2 and IL-4 caused glucocorticoid resistance in T-cells 81,82
and PBMCs83 which was able to be reversed with IFN-γ treatment. In these T-cells, p38/
MAPK activation was observed and was also abrogated by IFN-γ treatment or direct
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p38/MAPK inhibition. In T-ALL, the IL-4 overexpression was attributed to
glucocorticoid resistance because of hyperactivated lymphocyte cell specific kinase
(LCK). IL-4 stimulation alone was sufficient to confer resistance in these T-ALL cells
and PDXs and could be reversed with LCK gene silencing or inhibitors such as
dasatinib.84 Aberrant LCK activation in prednisolone resistant patients was associated
with upregulation of calcineurin/NFAT signaling and triggered IL-4 overexpression.
Also, IL-2 or TLR7/8 agonist stimulation caused glucocorticoid resistance in CLL cells
and could be reversed by treatment with the JAK inhibitor ruxolitinib.85
IL-7 Receptor/JAK-STAT Signaling
In T-lineage ALL, mutations in the IL-7 receptor signaling pathway genes (IL7R,
JAK1, JAK3), Ras pathway genes(KRAS, NRAS, NF1) and AKT were associated with
steroid resistance and poor outcome. These alterations were observed mostly in the early
thymic progenitor (ETP) or T Cell Leukemia Homeobox (TLX) ALL subtypes.
Expression of mutant IL7R, JAK1, mutant or wild type NRAS, or AKT induced steroid
resistance in T-ALL cell lines P12 Ichikawa or SUPT1), with no apparent change in Lasparaginase or vincristine response. Strong activation of both MAP Kinase (MEK and
ERK) and AKT signaling were implicated as causative mechanisms, and MEK, AKT and
mTOR inhibitors all enhanced steroid sensitivity.86 In another study of non-ETP T-ALL
JAK/STAT inhibition or IL7 removal was able to overcome glucocorticoid resistance.87
Avoiding Apoptosis
As noted in the initial description of the “Hallmarks of Cancer”, resisting cell
death and avoiding normal apoptosis is a key factor in defining the cancer phenotype.88,89
Thus, it stands to reason that avoiding apoptosis would also be a “hallmark” of
glucocorticoid resistance in cancer. Arguably, because chemotherapeutics push cells
towards death through normal processes this pressure may act as a selection event for
cells that have advantageous changes in the apoptotic regulatory pathways. Apoptotic
pathways can be disturbed in glucocorticoid resistant ALL in two main ways either there
is decreased pro-apoptotic protein expression or function that normally promote apoptosis
or there is higher expression of anti-apoptotic proteins either of which will disrupt the
balance of the cell’s ability to carry out its cell death program in response to
glucocorticoid treatment.
Pro-apoptotic Mechanisms
BCL2L11 (Bim)
The most well described pro-apoptotic protein involved in both the mechanism of
action of glucocorticoids and resistance to them in ALL is BIM (BCL2L11). It has been
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well described that glucocorticoid treatment induces BIM in leukemia cells.90-92 In a
study of thirty matched patient bone marrow samples at either day 0 or day 8 following
prednisolone monotherapy 25/30 patients (83%) had good response to PRED.
Differential BCL2 family expression showed that the pro-apoptotic protein BIM showed
significantly higher induction by prednisolone treatment in prednisolone responsive
patients when compared to poor responders. Furthermore, BIM expression was highly
predictive of response to prednisolone independent of molecular subtype, and BIM
knockdown in leukemia cell lines caused glucocorticoid resistance.93 Recently, a study of
genome-wide lymphocyte specific open chromatin identified an intronic GR binding
region (IGR) at the BIM locus in a glucocorticoid sensitive cell line ALL-54S that was
not observed in resistant cell line ALL-50R. Dexamethasone treatment induced much
greater CTCF binding at the BIM IGR in the ALL-54S than ALL-54R. The BIM IGR
was determined to be necessary mediator in the process of glucocorticoid induced cell
death and resistance.94
PMAIP1
PMAIP/Noxa which is a pro-apoptotic protein involved in the degradation of antiapoptotic MCL-1, and it has been shown that unlike BIM which is induced by activation
of the glucocorticoid receptor to be directly repressed by treatment with glucocorticoids
which may be a secondary effect of glucocorticoid treatment not related to its effect on
resistance.95 PMAIP has also or been proposed to be important for the regulation of
glucocorticoid sensitivity in leukemia cells96 and may be regulated by phosphorylation
state of the glucocorticoid receptor at either S211 which denotes active GR being
imported to the nucleus or S226 which is a marker for GR nuclear export which is
associated with GR inactivity.97
Anti-apoptotic Mechanisms
BCL2
The opposing mechanism to loss of pro-apoptotic protein induction (e.g. BIM)
leading to resistance is defective repression of or higher expression of anti-apoptotic
protein expression. The namesake of this class of proteins is known as BCL2 (B-cell
lymphoma 2). Opposing regulation of BIM and BCL2 modulates the resistance of acute
lymphoblastic leukemia to glucocorticoid induced apoptosis in both cell lines and patient
derived xenografts (PDXs).95 In prednisolone resistant PDXs, GR was not able to bind at
the KLF13 promoter and subsequent KLF13 expression was not increased resulting in
sustained high expression of MYB and its target BCL2.98
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MCL1
Another anti-apoptotic member of the BCL2 family MCL1 was highly expressed
in glucocorticoid resistant pediatric ALL80 and MLL rearranged infant ALL.99 Treatment
with rapamycin (mTOR inhibitor) was able to induce sensitivity to glucocorticoids
through an unknown mechanism of MCL-1 repression after being discovered as a
potential glucocorticoid sensitizing agent in a chemical genomics screen100 Obatoclax, a
pan inhibitor of BCL-2 family proteins, could also overcome MCL-1 associated
glucocorticoid resistance in ALL cell lines. Recently, a specific MCL-1 inhibitor was
been developed which may provide new ways to target this in glucocorticoid and other
BCL2 inhibitor resistant cancers.101
Smac/Diablo
BV6,a Smac/Diablo mimetic compound synergized with glucocorticoids in
patient derived xenografts of leukemia cells and in leukemia cell lines. This represents a
distinctly different pathway from traditional BCL2 family in resistance to glucocorticoid
treatment mediated through the ripoptosome. This may function independently of the
glucocorticoid receptor because some of the most significant effects were observed in the
Reh leukemia cell line which harbors a homozygous nonsense mutation in the
glucocorticoid receptor.102
Kinase Signaling
Ras/MAPK Pathway
Ras pathway mutations (KRAS, NRAS, NF1, FLT3 and PTPN11) are common at
diagnosis in childhood ALL (ranging from 35-44%), but it has been shown that clones
are retained at relapse in many cases, and that the incidence of relapse is higher in cases
with Ras pathway mutations.103,104 Some Ras pathway mutations were found to be
acquired (38.9%), but in many cases the mutations were present at initial diagnosis in
bulk sequencing. This does not preclude the possibility of low frequency mutations that
evade detection at diagnosis which was addressed in this study with some success and
may be further understood as single cell sequencing methods improve.105 Ras mutations
have also been shown to have a direct impact on the prognosis of MLL-rearranged infant
ALL they had higher white blood cell counts at diagnosis and also were more resistant to
glucocorticoids in vitro.106 A study in T-ALL patients with JAK1 or KRAS mutations
were more steroid resistant and had poorer prognosis than non-mutated patients. Ectopic
expression of mutant or wildtype NRAS confirmed the clinical finding and induced
steroid resistance in T-ALL cell lines.86 Furthermore, KRAS G13V mutations were
associated with ex vivo prednisolone resistance in patients. Consequently, Ras mutations
have been proposed as a predictive biomarker for treatment with MAPK inhibitors.
Downstream inhibition of the MAP kinase pathway via trametinib was able to synergize
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with glucocorticoids reducing resistance in ALL cell lines and primary patient leukemia
cells. Knock down of MAPK family members MEK2 and MEK4 was also able to
sensitize ALL cell lines.107

PI3K/AKT/mTOR Signaling
mTOR (mechanistic Target of Rapamycin) kinase signaling is an important
signaling pathway for a number of cellular functions (e.g. growth, survival and
autophagy) and has arisen as a central regulator of cellular homeostasis in response to
nutrient deprivation and other external insults.108 Genes both upstream and downstream
of mTOR have been identified as important in resistance of leukemia to glucocorticoid
induced apoptosis. AKT phosphorylation of mTOR in B and T lineage ALL cell lines
was able to impair glucocorticoid induction of apoptosis by increasing the expression of
MCL-1 and as stated previously it was seen that sirolimus (rapamycin) was able to
sensitize cells and reverse MCL-1 mediated glucocorticoid resistance.100 Subsequent
investigation showed that the glucocorticoid sensitization induced by mTOR inhibition
was facilitated by autophagy dependent necroptosis mediated through RIPK1 kinase.109
Another study showed that AKT phosphorylates GR at S134 and decreases its
nuclear localization blocking downstream transcriptional targets of GR, and that AKT
inhibitors can sensitize cells to glucocorticoids.110 Downstream mechanisms of this
pathway have also been associated with glucocorticoid resistance. AKT phosphorylation
inhibited BAD (a pro-apoptotic BCL2 member) and direct AKT mediated
phosphorylation of XIAP (an anti-apoptotic factor) prevents its ubiquitination and
degradation.111 Upregulation of metabolic pathway genes by AKT was associated with
glucocorticoid resistance in T-ALL by acting in direct opposition to the metabolic
inhibition caused by glucocorticoids treatment.112 A genome-wide shRNA screen in the
NALM-6 B-precursor ALL cell line identified PI3K pathway genes (PIK3CB2, PIK3CD
and IL7R) were associated with resistance to glucocorticoids through their interaction
with the B-cell receptor. Idelalisib (PI3Kδ inhibitor) treatment or knockdown of
endogenous PI3K inhibitory phosphatase PTEN sensitized cells to glucocorticoids in BALL.113
Furthermore, inhibition of the de-ubiquitinating enzyme USP9X (Ubiquitin
Specific Peptidase 9 X-Linked) which is highly expressed in B-ALL sensitized cells to
prednisolone induced apoptosis, and when knocked down in the RS4;11 leukemia cell
line downregulated MCL-1, BCL-2/BCL-XL and increased BAX levels. This was
attributed to reduced mTORC1 phosphorylation of its substrate S6K1.114
Src/Fyn/Lck Pathway
The Src-family kinases Lck and Fyn are critical in T-cell receptor (TCR)
transduction.115 It was shown that in MLL-rearranged infant ALL that overexpression of
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S100A8 and S100A9 was associated with prednisolone resistance because of failure of
cells induce free cytosolic calcium Ca (2+), and this was mitigated by treatment with the
Src kinase inhibitor PP2.116 Also, high ANXA2 expression and activation via Src kinase
phosphorylation requiring its adapter protein p11 (S100A10) caused prednisolone
resistance in MLL-rearranged infant leukemia. shRNA knockdown of ANXA2, FYN, LCK
or S100A10 all were individually sufficient to inhibit ANXA2 phosphorylation and cause
sensitization to prednisolone.117 EMP1 (a gene involved in adhesion to stromal cells) was
associated with poor prognosis in B and T-ALL due to its association with prednisolone
resistance. Pathway analysis confirmed that EMP1 signals through the Src kinase family
and that this is a possible mechanism for its normal function in maintaining interactions
with the stromal microenvironment.118 As described above the association with LCK and
the IL-7 receptor pathway has been described in great detail in T-ALL. Collectively,
these data suggest that Src kinase family inhibitors are a promising option for therapeutic
intervention to mitigate glucocorticoid resistance in both B and T lineage ALL.
cAMP/AMPK Pathway
cAMP signaling is a well described signaling pathway and has implications in a
variety of phenotypes. One important component of cAMP signaling are
phosphodiesterases (PDEs) which degrade the phosphodiester bond in second messengers
cAMP and cGMP. They regulate the localization, duration and amplitude of cAMP
signaling within subcellular domains.119 It was first discovered that germline PDE4B
mutations were associated with relapse in pediatric ALL.19 It was further observed that
PDE4 inhibitors could alter the levels of the glucocorticoid receptor in CLL cells and
sensitize them but not in circulating hematopoietic cells.120 AMPK, an inhibitory kinase
for the conversion of ATP to cAMP which is a critical step in cAMP signaling sensitized
cells to glucocorticoids when inhibited which is in concordance with previous findings.77
Epigenomic Mechanisms of Glucocorticoid Resistance in ALL
Chromatin Modifiers (SWI/SNF)
The glucocorticoid receptor acts on many of its targets through direct
transcriptional activity. To bind directly to DNA and effectively modulate transcription
dynamic structural changes in chromatin are required. The SWI/SNF chromatin
remodeling complex is essential in this efficient restructuring of chromatin, especially in
the case of nuclear receptors.121,122 SWI/SNF components SMARCA4, SMARCB1 and
ARID1A all exhibited decreased expression in glucocorticoid resistant primary acute
lymphoblastic leukemia.123 SNPs in the promoter of SMARCB1 were also associated with
glucocorticoid sensitivity in lymphoblastoid cell lines which was attributed in part to the
alteration of a PARP1 binding site.124
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Histone Modifiers
Another way the chromatin landscape can be regulated is through posttranslational modification of histones which are proteins that the DNA is “wound” around
in its heterochromatin (closed) state. One major amino acid residue that is known to be
modified with important functional consequences in signaling for chromatin remodeling
complexes to act on DNA and either open or close it are lysine residues which are most
commonly either acetylated in the cases of open chromatin 125-127 or mono-, di- or trimethylated which can signal the chromatin to be in a closed state.128 These marks are
commonly found at promoter or enhancer regions in the DNA where the regulation of
gene expression is most highly affected.
One family of enzymes that catalyzes the methylation of histones are the lysine
methyltransferases (KMT2A or KMT2D) these were originally referred to as MLL (mixed
lineage leukemia) genes. Commonly altered in ALL, MLL-rearranged leukemias have
been designated as a unique molecular subtype. MLL Patients exhibit poor response to
therapy and are more commonly younger individuals, especially infants.9,129 Nearly 80%
of infant leukemias have MLL rearrangement, and it has been shown in several studies
that in both B-lineage leukemia and T-lineage leukemia MLL rearranged leukemias were
more resistant to glucocorticoids especially those with the t(4;11) translocation.112,130 In a
study in T-ALL, it was shown that changes in expression in wild-type (non-rearranged)
MLL also can contribute to glucocorticoid resistance.130
Other epigenomic factors may be potential targets to combat glucocorticoid
resistant leukemia. In GC poor responsive patient leukemias where the BIM gene is
silenced the HDAC inhibitor vorinostat was able to recover antileukemic efficacy in
leukemia xenograft models of ALL.131 Overall, epigenomics is still a burgeoning field of
research, and there is great effort to understand the epigenomic landscape of leukemia
especially in the case of glucocorticoid resistance. With advances in the ability to
interrogate and deconvolute the 3D interactions of chromatin and the epigenetic “code”
the future of epigenomics in the context of drug resistance is very promising.
B-Cell Development Factors
ALL development can often be attributed to specific genetic lesions or
developmental blocks in normal development of B-cells leading to aberrant growth of
leukemic cells that can ignore normal differentiation signals leaving cells in an immature
state. Normal B-cell development is controlled by a number of transcription factors
known to regulate lineage specific development.132
PAX5
PAX5 is a transcription factor that is critical in mediating the maturation of Bcells by repressing the expression of non-lineage specific genes and upregulating the
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expression of genes involved in B-lymphoid signaling.132-134 Alterations in PAX5 increase
susceptibility to and are common in acute lymphoblastic leukemia occurring in over 40%
of all cases. They exert their leukemogenic effect by altering the normal B-cell
transcriptional program leading to aberrant growth and malignant phenotype. 12,135 PAX5
was differentially expressed between glucocorticoid sensitive and resistant leukemias,
and this resistance was associated with the altered maturation state of the cells. In patient
derived pre-B ALL cells, expression of a dominant negative mutant of PAX5 was able to
cause glucocorticoid resistance. Also, cells expressing a PAX5 haploinsufficient mutant
were glucocorticoid resistant which could be recovered by addition of wild-type PAX5.77
IKZF1
IKZF1 is another important B-cell developmental factor that is frequently mutated
in ALL. It has been associated with poor prognosis likely due to its high frequency in
thehigh-risk ALL subtypes BCR-ABL1+ and BCR-ABL1-like ALL.12,13 Similar to PAX5,
patient derived B-ALL expressing haploinsufficient IKZF1 exhibited glucocorticoid
resistance and this could be recovered by addition of wild-type IKZF1. Dominant
negative IKZF1 was able to cause resistance when transduced into wild-type patient
derived B-ALL cells. It was postulated that PAX5 and IKZF1 act as metabolic
gatekeepers in which loss of function increased glucose uptake and ATP levels which
was likely causative in the ability to resist the effects of glucocorticoid induced apoptosis.
This was proposed as an explanation for why glucocorticoids are effective against
lymphoid but not myeloid malignancies.77 CRISPR/Cas9 screening was performed to
identify transcriptional targets of PAX5 and IKZF1 and three genes were identified
NR3C1 (GR), TXNIP (involved in inflammation, reactive oxygen sensing and glucosefeedback) and CNR2 (cannabinoid receptor 2). They confirmed these initial findings by
showing that TXNIP and CNR2 agonists were able to strongly synergize with
glucocorticoids.77
Drug Metabolism and Transport
GSTM1 is an enzyme involved in detoxification, metabolism of xenobiotics and
the negative regulation of apoptosis signaling cascades. Germline genetic polymorphisms
in GSTM1 were associated with a greater risk of relapse in pediatric high risk ALL with
corresponding decreased gene expression in GSTM1.136 GSTM1 inhibited glucocorticoid
induced apoptosis by suppressing Bim expression in two T-ALL cell lines, presumably
via down-regulation of both p38-MAPK and upregulation of NF-kappaB p50.137
There is evidence that enzymes involved in the metabolism of steroids such as
11β-hydroxysteroid dehydrogenase 2 (HSD11B2) which converts active glucocorticoids
into inactive glucocorticoids which cannot bind to GR. HSD11B2 inhibition by
carbenoxolone made T-ALL cell lines more sensitive to glucocorticoid treatment.138
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Non-genomic Mechanisms of Glucocorticoid Resistant ALL
miRNAs have been shown to be important in the post-transcriptional and posttranslational regulation of gene expression. Recently, a set of miRNAs mir-27a, mir-223
and mir-708 were found to be associated with clinical outcome in childhood ALL, but in
this study only miR-708 was found to be associated with in vivo response to
glucocorticoids.139 miR-128b was differentially expressed in relapsed vs. non-relapsed
childhood ALL139 and was shown to be associated with poor prognosis in MLL-AF4
ALL along with miR-221 and downregulation of these miRNAs led to glucocorticoid
resistance. Re-expression of both miR-128 and miR-221 (which down-regulates
CDKN1B) sensitized two ALL (MLL-AF4) cell lines to glucocorticoids.140 However,
miR-221 has conflicting reports as a study in multiple myeloma showed that inhibition of
miR-221 sensitized cells to glucocorticoids.141 These findings illustrate one example of
how non-genomic mechanisms may provide promising discoveries for the future of drug
resistance in ALL.
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CHAPTER 3.

METHODOLOGY*
Patients

The sensitivity of primary leukemia cells to prednisolone was determined ex vivo
for a total of 444 patients aged 18 years or younger with newly diagnosed ALL. Of these,
298 patients were enrolled in the St. Jude Total Therapy XV (TOTXV, NCT00137111)
or XVI (TOTXVI, NCT00549848) protocol, the initial 225 were the “discovery” cohort
and the subsequent 73 constituted a validation cohort. We also used publicly available
mRNA expression data and prednisolone LC50 values for 145 European pediatric ALL
patients previously described in detail 62 as a second validation cohort. Also, 45 Tlineage leukemia patients from St. Jude Total Therapy XV or XVI protocols were
included for investigating ALL subtype differences in prednisolone sensitivity. Leukemia
cells from an additional cohort of 335 patients with ALL were studied: 226 pediatric
patients (14 St. Jude Total Therapy XV, 182 St. Jude Total Therapy XVI [73 from
validation cohort] and 30 from St. Jude Total Therapy XVII) and 109 adult patients (66
from the Eastern Cooperative Oncology Group, 33 from M.D. Anderson Cancer Center, 8
from the University of Chicago and 2 from the Alliance for Clinical Trials in Oncology)
were included to further assess the expression of CELSR2; in a subset of these patients
(n=96) the sensitivity to venetoclax was measured. The level of minimal residual disease
(MRD) in bone marrow was determined by flow cytometry and/or polymerase chain
reaction at day 15-19 and after completion of induction, as previously described.24
Written informed consent was obtained from all patients or their parents or guardians.
The use of these samples was approved by the institutional review board at St. Jude
Children’s Research Hospital.
Mice
Unconditioned mice were seven to nine weeks old when injected with leukemia.
Daily observations were carried out on the mice and they were sacrificed when leukemia
cells reached 50% in the peripheral blood, or the veterinarian determined they showed
clinical symptoms (ruffled fur, respiratory stress, hindlimb paralysis, or significantly
decreased mobility).This study was performed in accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health. Mice were maintained in an American Association of Laboratory Animal Care
accredited facility and were treated using a protocol approved by the St. Jude Animal
Care and Use Committee (Protocol Number: 580-100498) in accordance with NIH
guidelines. NOD. Cg-Prkdc scid Il2rg tm1Wjl/SzJ (NSG) mice were obtained from the
St. Jude colony for all experiments and were kept under pathogen free conditions.

-------------------*
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Animals were sacrificed by carbon dioxide asphyxiation using the gradual
displacement method, consistent with the American Veterinary Medical Association
Guidelines for the Euthanasia of Animals: 2013 Edition. Great efforts were made to
minimize suffering.
Human Leukemia Cell Lines
Human B-lineage acute lymphoblastic leukemia cell lines (NALM-6 and 697)
were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and
2mM L-glutamine at 37º C with 5% CO2. CELSR2 knockdown cell lines were generated
in NALM-6 and 697 cells transduced with lentivirus containing short-hairpin RNA
targeting CELSR2 (MISSION pLKO.1-puro shRNA TRCN0000011243; sequence : 5’CCGGGCCACTGAAGACACTGACATACTCGAGTATGTCAGTGTCTTCAGTGGC
TTTTT or TRCN0000011240 sequence: 5’CCGGCGCTTGGACAAAGGGAACTTTCTCGAGAAAGTTCCCTTTGTCCAAGCG
TTTTT; Sigma-Aldrich) or a non-targeting control (MISSION pLKO.1-puro Nonmammalian shRNA control (SHC002); Sigma-Aldrich), and selected in media containing
5µg/mL puromycin. PAX5 knockdown NALM-6 cell lines were generated by transducing
with lentivirus short-hairpin RNA targeting PAX5 (MISSION pLKO.1-puro shRNA
TRCN0000016059; sequence: 5’CCGGCCCTCAGTATTCCTCGTACAACTCGAGTTGTACGAGGAATACTGAGGG
TTTTT; Sigma-Alrich) or a non-targeting control (MISSION pLKO.1-puro Nonmammalian shRNA control (SHC002); Sigma-Aldrich), and selected in media containing
5µg/mL puromycin.
GR rescue experiments were performed by stable lentiviral transuction of nontarget control or shRNA targeting CELSR2 transduced NALM-6 cells with plx304 vector
(Addgene) with cDNA of GR (Origene; RC220189) tagged with V5 or GFP control.
These cells were then selected with 15µg/mL Blasticidin and 5µg/mL Puromycin and
assessed for in vitro prednisolone sensitivity at 72hr.
To constitutively express Cas9 in the NALM-6 cell line, we transduced cells with
lentivirus containing the Cas9 expression vector (Addgene: 52962) and selected cells in
media containing 15µg/ml blasticidin (Sigma-Aldrich).
Prednisolone Ex Vivo Resistance Assay
Primary leukemia cells were isolated from the bone marrow or peripheral blood of
newly diagnosed ALL patients, and tested for prednisolone sensitivity by MTT assay, as
previously described.75,80 In brief, cells were seeded in a 96-well plate at a concentration
of 2x106 cells/mL for primary cells, in phenol red-free RPMI 1640 medium
supplemented with 20% FBS, 2 mM L-glutamine, 100 IU/mL penicillin, 100 µg/mL
streptomycin, 0.25 µg/mL Amphotericin B, and 1X insulin-transferrin-selenium
supplement or 2.0x105 cells/mL for ALL cell lines, in phenol red-free RPMI 1640 with
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10% FBS and 2mM L-glutamine. In wells of round-bottom 96-well plates, 80 µL of each
cell suspension was combined with 20 µL of methylprednisolone at varying
concentrations (Solu-Medrol®, Pfizer) diluted serially. Plates were incubated at 37º C in
5% CO2 for a total of 96 hours (primary ALL) or 72 hours (ALL cell lines).10 µL of 5
mg/mL MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-tetrazolium bromide) was added
to each well for the final 6 hours of incubation. Acidified isopropanol was used to
solubilize formazan crystals and absorbance was measured at 562 nm with a background
correction of 720 nm, (uQuant, BioTek Instruments). For ALL cell lines, the
CellTiterGlo® Assay (Promega) was used to measure prednisolone LC50. For patients
enrolled on St. Jude TOTXV or TOTXVI protocols LC50 was determined at St. Jude
Children’s Research Hospital. Publicly available data from European patients had been
previously assayed in The Netherlands by MTT as previously described.80 Patients from
all cohorts were classified as resistant (≥ 64µM) or sensitive (<0.1 µM), according to
previously described criteria.75 For a subset of patients included in the whole exome
sequencing mutation analysis who did not have prednisolone LC50 determined, their
dexamethasone LC50 values were used after multiplying by a factor of eight to adjust for
the difference in potency.
Gene Expression by Microarray
Total RNA was harvested from primary leukemia cells obtained from 203 patients
at diagnosis using TRI Reagent (Molecular Research Center, Inc.). Gene expression was
assessed in the Hartwell Center for Bioinformatics & Biotechnology at St. Jude
Children’s Research Hospital using either HG-U133A (GPL96) or HG-U133 Plus 2.0
(GPL570) microarray platforms (Affymetrix), according to the manufacturer’s protocol.
The “affy” Bioconductor R-project package or Affymetrix Microarray Suite version
5.080,144,145 was used to implement the MAS5 algorithm for processing the gene
expression data.
Gene Expression by RNA Sequencing
Total RNA was harvested from 217 patients enrolled on St. Jude protocols (13
from St. Jude TOTXV, 176 from St. Jude TOTXVI and 26 St. Jude TOTXVII) and 103
adult patients (62 from the Eastern Cooperative Oncology Group, 32 from M.D.
Anderson Cancer Center, 7 from the University of Chicago and 2 from the Alliance for
Clinical Trials in Oncology), and total stranded RNA sequencing was performed. Total
RNA was harvested from primary ALL samples using TRI reagent. In ALL cell lines,
total RNA was isolated using the RNAeasy Mini kit (Qiagen), and stranded mRNA
sequencing was performed. All RNA sequencing was carried out via the Illumina HiSeq
platform by the Hartwell Center for Bioinformatics and Biotechnology at St. Jude
Children’s Research Hospital.
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DNA Methylation Analysis
DNA was isolated from the bone marrow or peripheral blood of 178 newly
diagnosed leukemia patients using the Blood and Cell Culture DNA kit (Qiagen). DNA
methylation status was interrogated genome-wide using either the Infinium
HumanMethylation27 BeadChip kit or the Infinium HumanMethylation450 BeadChip kit
in accordance with the manufacturer's protocol (Illumina). HumanMethylation27
BeadChip experiments were performed at either the Emory Integrated Genomics Core
(EIGC; Atlanta) or the Wellcome Trust Centre for Human Genetics Genomics Lab
(Oxford). HumanMethylation450 BeadChip experiments were performed at the Heflin
Center for Genomic Science at the University of Alabama at Birmingham (Birmingham,
Alabama, USA). Beta–values (β)146 were derived from the raw output for each CpG site.
Individual loci were grouped according to ENCODE criteria147; DNA methylation status
was classified as: hypomethylated (β ≤0.2), hemimethylated (β >0.2 < 0.6) or
hypermethylated (β ≥ 0.6).
SNP Analysis
DNA was extracted from ALL cells from bone marrow or peripheral blood
samples from 184 newly diagnosed patients using the Blood and Cell Culture DNA kit
(Qiagen). DNA samples were genotyped using the Affymetrix GeneChip Human
Mapping 500K set or the SNP 6.0 array (Affymetrix). The arrays were scanned, and
genotype calls were made using the BRLMM algorithm as implemented in the GTYPE
software (http://www.affymetrix.com/products/software/specific/gtype.affx) as
previously described.148 SNPs were excluded for call rates of less than 95% amongst all
patients or a minor allele frequency less than 1%. SNPs were annotated to genes for
further comparative analysis between methods only if they were an expression
quantitative trait locus (eQTL) as defined by Haploreg v 4.1.
miRNA Expression Analysis
Total RNA was extracted from ALL cells isolated from bone marrow or
peripheral blood samples from 163 newly diagnosed patients. All microRNA expression
microarrays were analyzed in the Hartwell Center for Bioinformatics & Biotechnology at
St. Jude Children’s Research Hospital, as previously described.149 High-quality RNA was
hybridized to miRCURY LNA 10.0 (GPL7722) generated from ready to spot probe sets
or preprinted 6th generation miRCURY LNA microRNA microarrays (GPL11434) in
accordance with the manufacturer’s protocol (Exiqon, Woburn, MA). Upon removal of
background signal data were log2 transformed and quantile normalized prior to analysis.
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Copy Number Alteration Analysis
DNA was extracted from ALL cells isolated from 184 newly diagnosed patient
bone marrow or peripheral blood samples, as described above to obtain data with the
Affymetrix Genome-wide Human SNP Array 6.0. To identify copy number abnormalities
for each sample, the SNP arrays were processed as follows. For each probe-set, we
computed the raw signal as the mean of the log-transformed CEL file intensities across
all probes annotated to that probe-set. Noting that the distribution of raw signals differed
according to probe type (copy number or genotyping), we then transformed raw signals to
have the same mean and variability across probe types. Probes were categorized by
quintiles of the GC content according to Affymetrix annotations. For each probe
category, the raw signals were median centered. After median centering, a pooled
standard deviation estimate was computed as the square root of the average of first
differences 150 within each probe category. Then, for each probe category, the mediancentered signals were divided by the Rice (1984)150 standard deviation estimate based on
first differences. After this re-centering and scaling, the distribution of signals for each
probe category had median 0 and Rice standard deviation of 1. These signals were then
multiplied by the pooled standard deviation so that the relationship of the processed
signals to actual copy number more closely approximated that of the original signals.
After this re-scaling, all probe categories had signal distributions centered at zero with
scale comparable to that of the original raw signals. These processed signals were
provided as input to the circular binary segmentation algorithm.151,152 The endpoints of all
segments were used to empirically partition the genome into a series of non-overlapping
regions to represent results in a matrix form with the segment mean of each subject
(matrix column) for each region (matrix row). These segmentation results were postprocessed by first inferring copy numbers (CN=0, 1, 2, 3, 4) based on segment means.
Histogram of segment means for all inferred segments were generated and a clear
trimodal distribution was shown with center mode at 0 corresponding to CN=2. The
nadirs (+/-0.2) between the center mode and two adjacent modes were chosen to be used
as cutoff for copy number gain or loss. Among copy number loss segments, we further
assigned those with mean less than 3 median absolute deviation(MAD) from the median
of all CN loss segments as CN=0. Similarly, we assigned those segments with mean
above 3 MAD from the median of all CN loss segments as CN=4. After copy number has
been assigned, adjacent segments with same CNs across all patients in the study cohort
were further collapsed for downstream analysis. The detection, prevalence estimates, and
association results for CNAs should be considered preliminary in that they are limited by
the resolution of the microarray platforms used in this study. These analyses were
performed using the DNAcopy package developed for R software.
Whole Exome Sequencing Coding Variants
DNA was extracted from ALL cells isolated from bone marrow or peripheral
blood from 201 newly diagnosed pediatric B-lineage leukemia patients using Blood and
Cell Culture DNA kit (Qiagen). Alignment was performed to the reference human
genome assembly GRCh37-lite with BWA and analyzed as previously described using
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matched germline sample as reference for somatic mutations.153-155 Mutations were
filtered for non-synonymous variants only in the coding region (excluding 3’ and 5’UTR
variants). They were then aggregated to individual genes and gene-level clustering via the
Ward method was performed using Euclidean distance.
Hierarchical Clustering of Genomic Features
Each individual genomic feature type (mRNA, miRNA, DNA methylation, SNP,
CNA and SNV/Indels) was rank ordered based by their linear regression p-values for
association with prednisolone LC50. Instanced hierarchical clustering was performed in a
stepwise fashion beginning with the two most statistically significant probes. For each
instance, Fisher’s Exact Test (FET) was utilized to assess how well the clustered data
could segregate resistant and sensitive leukemias when the highest clade of the
dendrogram was split in two. Probes were added individually at each instance and
hierarchical clustering and Fisher’s Test calculations were repeated for up to 500 probes.
Fisher p-values for the different patient cohorts were combined using meta-analysis
(Stouffer’s method) and the combination of probe sets that generated the lowest metaanalysis p-value was used as the signature for each individual feature type. 110,000
rounds of permutation were performed on the data to determine the likelihood that the
observed meta clustering p-values for each feature was due to chance. Analyses were
carried out in R using packages gtools, gdata, bitops, caTools, gplots, and amap. All data
were clustered using the hcluster function in R using the “ward” method and distance
used was “correlation” for all features except WES (“Euclidean”) and SNPs (“binary”).
All FDR corrected values were calculated using the Benjamini-Hochberg correction
method for cutoffs of selected feature lists and can be found in Supplementary Tables
1-9 for each respective feature type.
Connectivity Among Genomic Features
To determine connectivity between mRNA expression and each of the other
genomic feature types, we compared expression levels with each genomic feature type
for all samples interrogated for both features.
Associations between DNA methylation and gene expression were deemed
significant if there was a negative and statistically significant (p < 0.05) association
according to linear regression (patient cohort included as a covariate), and the CpG site
was within 100 kb of the gene’s transcription start site. Connections between DNA
methylation probes found to be inversely associated with expression of genes in the
prednisolone resistance mRNA signature were included only if the methylation probe
was also significantly associated with prednisolone LC50 (p < 0.05).
Connections between miRNA expression and gene expression were required to
meet the following conditions: a negative association by linear regression (p-value <
0.05) and the gene’s transcript contains a miRNA binding site based in either of two in
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silico prediction databases (miRaNDA or miRDIP) or a database of experimental
evidence of biological connection from public databases (mirTarbase). Connections
between SNPs, CNAs, SNVs/Indels and gene expression were required to have a linear
regression p-value < 0.001 in both patient cohorts.
Genome-Wide CRISPR Knockout Screens
We transduced 12x106 NALM-6 human leukemia cells that were constitutively
expressing Cas9 protein with either GeCKOv2 library A or B by spinfection for 2hr at
568g at a MOI between 0.3-0.5 to ensure only one gRNA per cell, as previously
described.156 Both libraries contained 6 gRNAs per gene and 1000 non-targeting controls
and library A contained 4 gRNAs per miRNA. Cells were selected with 15ug/ml
Blasticidin (Cas9) and 5ug/ml Puromycin (gRNA) to ensure that cells contained both
gRNA and Cas9 protein. Representation of gRNAs was verified by sequencing the gRNA
region using a two-step nested PCR reaction to amplify the region, as previously
described.156,157 For each library, 2x107 cells were treated with 100µM prednisolone for
72hr. After 72hr, viability of these cells ranged from 10-20% for all treatments. Cells
were grown out until they reached >90% viability, and DNA was extracted using the
Blood and Cell Culture Maxi kit (Qiagen). The gRNA region was sequenced via Illumina
HiSeq 2500 using single reads in rapid run mode and gRNA enrichment/depletion
analysis performed using the MaGeCK algorithm.158,159 Genes that were not expressed
based on RNA-seq of the NALM-6 cell line were removed from the analysis, and at least
4 significant (p<0.005) gRNAs were required to be included in the gene-level knockout
reduced analysis. Gene level aggregation of gRNAs was performed using logit p-value
transformation method in the R package metap. Effect sizes were calculated as Cohen’s
D.
Integrated Gene Level (TAP) Analysis
To assess a known gene’s potential involvement in leukemia cell
sensitivity/resistance to prednisolone, we combined evidence from all six genomic
features within or in proximity to (50kb) every known human gene. Each genomic feature
was evaluated individually for its association with prednisolone LC50, features that were
significant (linear regression p <0.05) were included in the overall gene level model. A
hybrid permutation approach was used along with a non-parametric smooth CDF
(cumulative distribution function) with a variation diminishing spline to obtain a TAP
(Truncated Aggregation of P-values) statistic for every gene.160,161 Adaptive thresholding
was used, as previously described to define the threshold of significance.162 Genes
meeting this threshold were used to select top candidate genes for further analysis.
Annotation of genomic features to gene regions: We downloaded from the UCSC
<https://genome.ucsc.edu/index.html> the genomic locations of all 19,725 mapped
human genes. A genomic feature with genomic location information, (i.e. mRNA
expression probeset, CpG methylation marker, SNP, SNV/in-del from WES and CNV
segment) is annotated to a gene region if the feature is either inside the gene (between the
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beginning of the first exon and the end of the last exon), or within or overlaps with (in
case of CNV segment) the region 50 kb up and down stream of the gene.
Truncated Aggregation of P values (TAP) statistic: Each genomic feature annotated to a
gene region was tested individually for its association with the prednisolone LC50 by
linear regression, with treatment protocol (TOT-XV and TOT-XVI) as a covariate, the P
value of the t test of the regression coefficient on the genomic feature is obtained,
representing the level of statistical evidence on the genomic feature’s association with
LC50 (a single piece of evidence). The P values are then combined to form the TAP
statistic in a modified form of Fisher transformation Equation 3-1.

(Eq. 3-1)
where M is the number of genomic features interrogated on the various assay platforms
and annotated to the gene region; I(A) is the indicator of condition A, I(A)=1 (0) if A is
true (false); and δ is a truncation threshold which was set to 0.05 in our analysis
following.163 The truncation is included here to better contrast small P values out of a
possibly large set of P values (a gene region can contain dozens or hundreds of genomic
features).
Hybrid Permutation Test
Assessment of a gene region’s potential involvement in the biological process
underlying leukemic cells’ sensitivity/resistance to prednisolone was formulated by
testing the null hypothesis that none of the interrogated genomic features annotated to
gene region is associated with LC50, vs. the general alternative hypothesis which states
that the null hypothesis is false. The test can be carried out using the statistic T defined
above. To compute the statistical significance (P value) one needs to know (or adequately
approximate) the probability distribution of T under the null hypothesis. Notably this
statistic is not a sum of independent log-transformed P values because the genomic
features are generally related (e.g., SNPs in LD, reduced mRNA expression due to CpG
methylation, etc.), and the truncation adds more complexity. In principle a permutation
test can be performed, where in each round the LC50 and covariate data points are
randomly permuted together, and the P value of each individual genomic feature, and
then the test statistic T are recomputed based on the permutated data. In each permutation
round genome-wide association tests have to be conducted on several platforms, and to
reflect high significance level at least 100,000 permutations is necessary; this can be
extremely time consuming.
To introduce computational and statistical efficiency, we took a hybrid
permutation test approach with the following steps: (1) Perform a few hundred
permutation rounds to obtain a set of observations of the test statistic under the
(simulated) null hypothesis: T_b, b=1,⋯, B. The number of permutations was set to
B=200 in our analysis. (2) Transform the observations onto the unit interval [0,1] by a
probability integral transformation, 〖W_b=F_0 (T〗_b), b=1,⋯, B, where F_0 is the
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null cumulative distribution function (cdf) of the test statistic under the null hypothesis,
derived under the condition that the P values are independent. Clearly naively applying
this cdf to compute the statistical significance for a gene region will inflate the type-I
error rate because the P values are not independent. Our approach then is to properly
correct this cdf by combining permutation (resampling), probability integral
transformation, and non-parametric smoothing as described in the next two steps. (3)
Construct a nonparametric smooth cdf F ̂_W on [0,1] using the approach described in,161
where variation diminishing spline160 was chosen as the smoothing kernel for its good
numerical and analytical properties. (4) Construct an estimator of the cdf of T under the
null hypothesis by back-transformation F ̂_T (x)= F ̂_W (F_0 (x)). Here F ̂_W is a nonparametric correction to F_0. The P value is computed as P=1-F ̂_T (T_obs ). It is shown
in160 that proper non-parametric smoothing can introduce substantial efficiency. Results
from the simulation study (see below) show that this procedure works quite well even
with as few as 200 permutations.
Significance Threshold Adjusting for Massive Multiple Tests
The TAP test was applied to 19,725 gene regions, generating 19,725 gene-level pvalues. The significance threshold was determined by applying the adaptive threshold
criteria developed in,162 which has been implemented in R and applied to the 19,725 pvalues.
A Simulation Study
To gauge the operating performance of the TAP method, we conducted a
simulation study with 10,000 simulation rounds. We simulated the data of a gene region
mimicking our observed data on the NLRP3 gene region (chr1: 247529458-247662406
plus 50kb up and down stream), assuming 47 SNPs, 2 CpG methylation loci, 1 CNV
segment and 1 gene expression probe are measured. To maintain the LD structure of the
SNPs, we downloaded the genotypes of the 47 SNPs from the One-thousand Genomes
Project (http://www.internationalgenome.org/data), totally 2,504 samples. Then
nucleotides of the 47 SNPs in one copy of a chromosome were treated as a copy of a
pseudo-chromosome. Thus, we had 5,008 copies of pseudo-chromosomes from 2,504
samples. Those pseudo-chromosomes were randomly paired to form simulated genotypes
for the 47 SNPs. Methylation levels were considered as ordinal variables. For one
methylation loci, we assumed the probabilities of high, medium and low methylation to
be 0.4, 0.4 and 0.2 respectively, and for the other 0.3, 0.1 and 0.6 respectively. The copy
number status probabilities (loss, no change and gain) were set as 0.7, 0.2 and 0.1. The
logarithm of gene expression (log(expr)) was modeled by a linear relationship with the
genotypes of 2 selected SNPs (SNP1, SNP2), the 2 methylation loci (meth1, meth 2) and
the copy number locus (cn) Equation 3-2:
(Eq. 3-2)
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The continuous phenotype y was generated by a simple linear regression mode Equation
3-3.
(Eq. 3-3)
Here e and ϵ are independent random errors set to follow the standard N(0,1)
distribution. Different coefficient (beta) values were used to depict effect sizes (see tables
below); beta=0 corresponds to the null hypothesis. We simulated several scenarios
defined by two truncation thresholds δ=0.05,0.2, several different values of β, and a few
nominal significance levels. The sample size was set to n=300, and the number of
permutations was set to B=200 in all scenarios. Estimated power (sensitivity, rows for
β≠0) and level (1 minus specificity, row for β=0) are compiled in Table 3-1 and Table
3-2.
The TAP test by the hybrid permutation procedure can hold the nominal
significance levels well (good control on false positive probabilities); while provides
good statistical power (sensitivity) to detect meaningful effect sizes (|β|>0.3). As
expected, power/sensitivity decreased as the truncation threshold δ was relaxed from 0.05
to 0.2.
Statistical Significance of Top Candidate Genes
We estimated the probability that finding 15 genes by all three of methods of
genomic interrogation is due to chance by considering the two aspects in genome-wide
tests: the probability of capturing one non-associated gene by chance (producing a false
positive), and the multiplicity. First, for any given gene, let PG, TAP and CR be
respectively the event that the gene is captured by chance in the polygenomic, TAP and
CRISPR analyses. The CRISPR experiment is completely separate from the other two
analyses, and thus is fully independent. By conditional probability, the event of “being
captured in all three analyses” has the probability Equation 3-4:
(Eq. 3-4)
Because PG and TAP were done on the same cohort, the results of the two
analyses can be highly associated; which raises the concern of whether a false positive
captured in one analysis is also captured in the other analysis. Quantitatively this is
reflected by the conditional probability Pr(PG|TAP). We here conservatively assume that
this probability is very high, Pr(PG|TAP)=0.9. Pr(TAP) and Pr(CR)are the respective P
value thresholds in the TAP and CRISPR analyses, each was determined with accounting
for massive multiple tests: Pr(TAP)=0.00053838 and Pr(CR)=4.1707×10-8. Thus
π*=2.0209×10-11. Next consider multiplicity. Even if our results were presented at the
gene level, significance tests were performed on individual genomic features of mRNA
and microRNA expressions, methylation probes, SNPs, SNVs/in-dels from WES, CNV
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Table 3-1.

β
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5

Table 3-2.

β
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5

Estimated power TAP (δ = 0.05)
0.05
1
0.9979
0.9401
0.5456
0.1205
0.0475
0.1237
0.549
0.94
0.9978
1

Nominal significance levels α
0.01
0.005
0.9989
0.9998
0.97
0.8625
0.7512
0.4749
0.2725
0.106
0.0405
0.0141
0.0162
0.0047
0.0409
0.0131
0.2638
0.1016
0.753
0.4796
0.9697
0.8607
0.9979
0.9819

0.001
0.8899
0.5973
0.1944
0.03
0.0021
0.0009
0.0026
0.0235
0.1909
0.5883
0.8907

Estimated power TAP (δ = 0.2)
0.05
0.9997
0.9801
0.8196
0.404
0.1056
0.0493
0.1084
0.4027
0.833
0.9795
0.999

Nominal significance levels α
0.01
0.005
0.9919
0.9434
0.9192
0.7537
0.6077
0.3551
0.2022
0.079
0.0359
0.0088
0.0156
0.0038
0.0375
0.0091
0.1995
0.0729
0.6189
0.3549
0.9191
0.7405
0.9927
0.9479
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0.001
0.7333
0.3952
0.1037
0.0162
0.001
0.0003
0.0009
0.0098
0.107
0.3861
0.7344

segments and CRISPR probes. The mRNA and microRNA expressions, methylation
probes, SNPs, SNVs/in-dels from WES and CNV segments were tested twice (once in
PG and once in TAP), resulting in 1,861,210 tests; and there were 13,267 tests in
CRISPR. So, we regard the study-wide multiplicity as m=1,874,477. The number of
genes captured in all three analyses purely by chance, N, can be modeled by a random
variable following the Binomial(m,π*) distribution. Thus Pr(capturing ≥15 genes in all
three analyses purely by chance)=Pr(N≥15) which is described in Equation 3-5.

(Eq. 3-5)
Therefore, the probability of capturing 15 genes in all three analyses purely by chance is
extremely small (8.2x 10-79).
Single Cell RNA Sequencing
To interrogate the expression of genes at the single cell level in patients who were
either sensitive or resistant to prednisolone in vitro, primary patient ALL cells were
collected at diagnosis and incubated for 96 hours with or without prednisolone. Patient
cells were re-suspended at a concentration of 2x106 cells/mL in culture media, as
described above. On day zero, 80 µL of cells were plated in round bottom 96-well plates.
Cells were incubated for 4 days with either 63µM prednisolone or no drug, collected and
washed with 50 µL of PBS and 150µL total volume was collected. Both control and
treated samples were processed and subjected to single cell RNA-sequencing on the 10x
Genomics platform. The Cellranger software from 10x Genomics was used to
demultiplex each of the samples, align the demultiplexed reads to the hg19 human
genome, collapse PCR duplicate reads into UMIs, and generate a matrix of UMI counts
for each cell and Ensembl ID combination.
All UMIs aligning to ribosomal protein-coding or mitochondrial genes were
removed from the count matrices. Cells were removed if less than 500 genes were
detected from the remaining UMIs. UMI counts within a cell were normalized by
dividing each UMI count by the total UMI count across the cell, scaling by the median
total UMI count across all cells from the four samples, adding a pseudocount of one, and
taking the natural logarithm.
PCA was performed jointly on control and treatment samples from each patient.
The first 40 principal components of overdispersed genes were used to generate a twodimensional embedding of cells using the Barnes-Hut implementation of tSNE with a
perplexity of 30.164 Dispersion was calculated as described elsewhere165 and as
implemented in Seurat (https://github.com/satijalab/seurat), with overdispersed genes
being genes in each bin that have z-scores at or above 1.4 (n = 922 genes for sensitive
and n=663 for resistant).
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Cell-cell Euclidean distance matrices were computed jointly for control and posttreatment samples of each patient using the over-dispersed genes. Hierarchical clustering
of the cells using the Euclidean distance matrix was performed using the Ward method.166
Clusters were then identified using DynamicTreeCut, an iterative cluster partitioning and
agglomeration method.
Clusters with at least 20% of the component cells expressing CD19 were
classified as B cells. The null hypothesis that the proportion of CD19+ cells between
control and treatment samples for each patient was tested using the prop.test function in
R, and differential expression of genes was tested using the Wilcoxon rank sum test as
implemented in the Seurat R package. This resulted in seven clusters for the resistant
patient and eleven clusters from the sensitive patient (Figure 3-1a,d)
Clusters of the B-lineage leukemia cells were identified based on the expression
of CD19 in the component cells. Other cell types were identified by identifying the most
highly differentially expressed genes in each cluster that are known markers of
hematopoietic lineage (e.g. T-cells, red blood cells; Figure 3-1b,e). The sensitive patient
in our single cell analysis had a B-lineage ALL with P2RY8-CRLF2 fusion. The resistant
patient in this analysis had a BCR-ABL positive B-lineage ALL.
Immunoblot
Cells were pelleted at 500xg. Lysates were prepared in RIPA buffer (SigmaAldrich) containing cOmplete Protease Inhibitor Cocktail (Roche Life Science) and
PhosStop (Sigma-Aldrich). Equivalent amounts of extract (20 µg) were separated on 38% Novex Tris-Acetate polyacrylamide gels (Thermo Fisher Scientific) and transferred
to polyvinylidene fluoride (PVDF) membranes (0.2 µm). Non-specific binding was
blocked with 5% Milk in TBS with 0.05% Tween-20 for at least 1hr prior to incubation
of membranes with primary and secondary antibodies. Primary antibodies used were
rabbit anti-CELSR2 monoclonal (Cell Signaling; D2M9H) diluted 1:1,000, mouse antiBCL2 monoclonal (Cell Signaling;124) diluted 1: 1,000, mouse anti-BIM
monoclonal(Cell Signaling;C34C5) diluted 1:1,000, mouse anti GR(BD Biosciences ;
#611227) diluted 1:1,000 ,mouse anti p-JNK (Santa Cruz Biotech; sc-6254) diluted
1:500, rabbit anti cJun (Cell signaling; 9165), rabbit anti phospho-cJun Ser63 (Santa Cruz
Biotechnology; sc-822 ) diluted 1:500, rabbit anti NFAT1 (Cell Signaling ; 4389 ) diluted
1:1,000, SAPK/JNK (Cell Signaling ; 9252) diluted 1:1,000 , mouse anti GAPDH (Santa
Cruz Biotechnology; sc-47724), mouse anti PAX5 (Cell Signaling ;12709) diluted
1:1000mouse anti BCL2 (Cell Signaling; 15071) diluted 1:1000, mouse anti
glucocorticoid receptor (BD Biosciences; 611227) diluted 1:1000 rabbit anti LaminB1
(Cell Signaling; 12586) diluted 1:1000 and anti-β-actin (Sigma-Aldrich; A5441) diluted
1:100,000. Membranes were then incubated with appropriate HRP-Conjugated IgG
secondary antibodies (Jackson Immunoresearch) and developed with SuperSignal West
Femto chemiluminescent substrate (Thermo Fisher Scientific) prior to signal acquisition
using an Odyssey Fc Imager (LI-COR). Image processing and signal quantification were
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Figure 3-1. Single cell transcriptomics defines distinct expression signatures in
primary B-ALL cells
(a.) Clustering of bone marrow cells from a prednisolone sensitive patient (n=2,427
control cells; n= 924 treated cells) based on top 1000 most highly expressed genes (b.)
Identification of distinct cell populations in a prednisolone sensitive patient CD19+ Bcells (red), CD3E+ T-cells (blue), ALAS2+ Erythrocytes (purple) and CD14+
Macrophages (green) (c.) Control vs. treatment for all cell clusters in prednisolone
sensitive patient (red = control, blue = treated) (d.) Clustering of bone marrow cells from
a prednisolone resistant patient (n= 686 control cells; n=759 treated cells) based on top
1000 most highly expressed genes (e.) Identification of distinct cell populations in a
prednisolone resistant patient CD19+ (red) and CD3E+ T-cells (blue) (f.) Control (C) vs.
treatment (T) for all cell clusters in prednisolone resistant patient (red = control, blue =
treated)
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performed with Image Studio software (Version 4.0; LI-COR). Nuclear/Cytoplasmic
protein extraction was performed using the NE-PER Nuclear and Cytoplasmic Extraction
kit (ThermoFisher) using standard protocol.
ChIP-seq and ATAC-seq
ChIP-seq was performed as previously described.167 Briefly, 20 million NALM-6
cells were crosslinked using 1% formaldehyde and sonicated on a Diagenode Bioruptor
Plus sonicator. Chromatin immunoprecipitation was performed using 5µg anti-PAX5
antibody (Abcam, ab15164). ChIP-seq and input control libraries were run on an Illumina
HiSeq4000 next-generation sequencing machine using single-end 50bp sequencing, reads
were mapped to the hg19 reference genome using BWA and binding sites were called
using MACS2 peak caller. ATAC-seq was performed using the Fast-ATAC protocol.168
Briefly, 10,000 cells were transposed in a cocktail containing 1% digitonin.
Following transposition, DNA was collected using the Qiagen MinElute Reaction
Cleanup Kit (Qiagen #28204) and amplified for 5 cycles using barcoded Nextera PCR
primers. A quantitative PCR reaction was performed on an Applied Biosystems
QuantStudio 3 Real-Time PCR machine using 5uL of PCR product to determine the
additional number of PCR cycles required. PCR products were subsequently re-amplified
for the appropriate number of additional PCR cycles and DNA was size-selected using
SPRIselect beads (Beckman Coulter, B23317). ATAC-seq libraries were run on an
Illumina HiSeq4000 next-generation sequencing machine using paired-end 100bp
sequencing, reads were mapped to the hg19 reference genome using Bowtie2 and open
chromatin sites were called using the MACS2 peak caller.
Previously Reported Mechanisms of Prednisolone Resistance
To assess the performance of our agnostic polygenomic method to identify genes
that confer resistance to glucocorticoids, we used Illumina BaseSpace® Literature
Correlation Engine to perform a literature search to identify all genes previously reported
to confer resistance to glucocorticoids (performed January 2018). The search terms
“glucocorticoids, leukemia” were used for our initial search, with a secondary filter of
“resistance”. This resulted in 426 total publications, which we narrowed using the “genes
and proteins” tab set on the “top 1000” setting and exporting the list of top word cloud
tags that were found from our search. This list of word cloud tags was entered into the
HUGO database (https://www.genenames.org/cgi-bin/symbol_checker); the resulting list
was trimmed by removing unmatched terms. This generated a list of 347 unique genes
published through 2016. We also included genes published in papers from January 2017January 2018 that were found by a PubMed search using search terms “glucocorticoids,
resistance, leukemia” with results limited by publication date, yielding 27 additional
publications.
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For all genes included in our tabulation of known genes previously associated
with glucocorticoid resistance, we required a published report linking the gene to poor
patient response (i.e. remission induction failure, persistence of minimal residual disease
[MRD], or disease relapse) or glucocorticoid resistance as measured in primary ALL
cells and that the gene/pathway was confirmed through either direct manipulation or
chemical inhibition in a human cell culture model or patient derived xenograft (PDX).
Using the aforementioned methods and criteria, a table of “known mechanisms” was
generated (Supplementary Table 7) and comparisons were then made to genes
identified as significantly related to glucocorticoid resistance by our three methods
(polygenomic, TAP, CRISPR screening), using either all genes identified by any one of
these methods or using the subset of genes identified by two or more of these methods.
Direct matches of genes were considered the strongest evidence. Genes that were not
directly matched were considered to have an associated pathway component if they were
found by searching for the gene in STRINGdb with the following criteria: 1) Only 30
first shell interactors with a correlation > 0.7 (high confidence), 2) only “Text-mining”,
“Experiments”, “Databases”, “Co-expression” were used to define informative data
sources. In all cases, concordance of directionality of the relationship was required
between published genes and those discovered in our analyses.
NetBID Analysis to Identify Drivers of GC-Resistance in ALL Patients
One pitfall from the conventional gene expression analysis is that important
signaling proteins might not change at individual mRNA expression level, thus networkbased methods were used to infer master regulator activity which would help overcome
this pitfall. We applied the network-based integrative NetBID169 algorithm to identify
“hidden” drivers in GC-resistant primary leukemia cells (ALL cells from patients) using
gene expression profiles. First, NetBID used an improved version of ARACNE 88, an
information theory-based algorithm to reverse-engineer a B-ALL specific interactome
(BALLi) from RNA-seq profiles of B-ALL primary B-All patients (N=185) from
TARGET170 project against 1,673 transcription factors and 6,247 signaling proteins
annotated by Gene Ontology.171 With parameters NB=100, e=0 and p=1e-7, the datadriven BALLi resulted in 21,655 nodes and 830,213 edges. Then we applied ‘netbid’
function (signed=TRUE) in NetBID package, which used z-normalization and z-statistic
for activity inference and Bayesian linear modeling for differential activity analysis, to
compare resistant (level=3) versus sensitive (level=1) as well as intermediate (level=2)
vs. sensitive ALL patients from TOTXV and TOTXVI cohorts respectively and then
applied ‘netbidi’ function, which used Stouffer’s method, to integrate results from
TOTXV and TOTXVI cohorts that used two different microarray platforms (HG-U133A
and HG-U133_Plus_2). In TOTXV cohort, we observed and removed the batch effects
from sample source by using the “removeBatchEffect” function in limma.172 Finally, the
48 top drivers were selected by the following criteria: network size > 50, p < 5x10-5 in
TOTXVI and integrated (combined) analysis of highly-resistant vs. sensitive patients, and
that the intermediate vs. sensitive and the resistant vs. sensitive results were concordant.
The NetBID package can be found online at: https://github.com/jyyulab/NetBID.
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Drug Synergy Experiments and Response Surface Modeling
Relationship of response was determined when prednisolone was given alone or
in combination with three concentrations of venetoclax using both NALM-6 cells (10nM,
100nM, 1µM) and 697 cells (1nm, 10nm, 50nm). Concentration ranges of venetoclax
differed because of differences in sensitivity to venetoclax between the two cell lines.
Viability assays were carried out using Cell Titer Glo. In synergy experiments with
primary leukemia cells from patients, 1nM, 10nM and 100nM concentrations of
venetoclax were used to assess synergy with prednisolone. Response surface modeling, a
well-established method calculating synergy in drug combinations173,174 as implemented
in MATLAB version R2016a (MathWorks), was performed to evaluate changes in the
response of cells to prednisolone and venetoclax alone or in combination at three
concentrations (low, medium, high).175-177 A drug combination was considered
synergistic if the (α) which represents the change in response relative to additive model
was positive and antagonistic if this value was negative. Results were confirmed using
two other established models (Loewe’s Additivity and ZIP) using the synergyfinder R
package (data not shown).178
In Vivo Drug Combination Studies
NALM-6 cells were injected into non-irradiated 8-12 week old female NSG mice
(100,000 cells/mouse). Treatment was started three days post injection and continued
until the endpoint was reached for each mouse. Mice were treated with either continuous
dexamethasone (4mg/L) alone, venetoclax alone (50 or 100mg/kg), as previously
described179 or either dosage of venetoclax in combination with dexamethasone.
Dexamethasone was given daily in drinking water with tetracycline (1g/L; SigmaAldrich, St. Louis, MO), and half of each week the water contained Sulfamethoxazole
(600 mg/L) and trimethoprim (120mg/L; from Hi-Tech Pharmacal, Amityville, NY).
Mice were randomized following injection. Mice were sacrificed when they became
moribund for any reason, as determined by the veterinarian.
Flow Cytometry
Blood was collected from the retro-orbital sinus, facial vein, or tail vein of
anesthetized mice to assess engraftment of human ALL cells. Blood was lysed with the
BD FACS Lyse Wash Assistant (BD Biosciences, San Jose, CA). Cells were stained with
antibodies to human CD19 (eBioscience;45-0199-42, PerCP-Cy 5.5) and mouse CD45
(Tonbo; 20-0451-U100, APC). Samples were assayed on the BD LSR II or LSR Fortessa
(BD Biosciences) and analysis was performed with FlowJo version 10 (FlowJo, LLC,
Ashland, OR).
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Statistics and Reproducibility
All statistical analyses were performed using R software or Graphpad Prism 8
unless otherwise stated. For box plots unless stated explicitly, upper and lower values in
each box depict the 75th and 25th percentiles, respectively, the solid line represents the
median, and the top and bottom of each dashed vertical line depict the most extreme data
points that were no more than 1.5 times the interquartile range (75th percentile–25th
percentile) from the box. All bar plots are representing mean ± standard deviation (S.D.)
and each dot represents and independent experiment or sample. For all analyses
comparing means of groups student’s t-test was performed, Chi-Squared analysis was
used for MRD group data, linear model was used as the predominant method for
statistical significance in genome-wide analyses using LC50 as a continuous variable and
Fisher’s tests were used to describe clustering of genomic data vs LC50. Customized
methods were also used such as NetBID which relied on Bayesian inference and used zscores to report significance169 and the TAP method which utilized a hybrid permutation
and an adaptive thresholding approach to assessing statistical significance of higher order
problems.
Data Availability
DNA methylation, gene expression and ChIP-seq data are available at the Gene
Expression Omnibus (GEO) under accession GSE66708. miRNA data can be found at
GEO under the accession number GSE76849. Cell line RNA-seq data can be found at
GEO under the accession number GSE115384. Validation cohort #1 RNA-seq data from
73 of the 320 patients in the independent second cohort can be found at GEO under the
accession GSE115525. Additional RNA-seq data from validation cohort #1 (n= 247) can
be found at GEO under GSE124824. PAX5 CHIP-seq can be found at GEO under the
accession GSE115764. Cell line ATAC-seq data can be found at GEO under the
accession GSE129066. Genotype data can be found in dbGaP at
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000638.v1.p1
Code Availability
Code used to generate for the polygenomic and TAP analyses can be found on
GitHub at https://github.com/evanslabSJCRH/Polygenomic-Analysis. The NetBID code
can be found at https://github.com/jyyulab/NetBID. Any custom code generated for our
analyses not specifically listed here or in the text may be requested from Dr. William E.
Evans (William.Evans@stjude.org). All R packages or other software used are listed in
methods section for each relevant analysis.
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CHAPTER 4.

RESULTS*

Introduction
Drug resistance is a major cause of treatment failure for disseminated human
cancers.180 Acute lymphoblastic leukemia (ALL) has long served as a model for
developing curative chemotherapy for disseminated malignancies. Long-term diseasefree survival in childhood ALL has increased dramatically in recent decades, with 5-year
event-free survival approaching 90%, yet drug resistance makes it less curable in adult
patients and it remains a leading cause of cancer deaths in children.21 Much of the
improvement in cure rates can be ascribed to refinement of therapy based on improved
understanding of clinical and biological characteristics of the disease and the
intensification of treatment when there is poor early response or persistence of minimal
residual disease (MRD).21,47,181,182 Glucocorticoids, such as prednisone (PRED) and
dexamethasone (DEX), are essential components of curative combination chemotherapy
for ALL in adults and children31 and the intrinsic sensitivity of ALL cells to
glucocorticoids, as measured ex vivo, is predictive of treatment outcome (event-free
survival or survival) in childhood ALL. 48,49,180,183 Although several mechanisms of
leukemia cell resistance to glucocorticoids have been identified,33,184-186 the genomic and
epigenetic determinants of de novo glucocorticoid resistance remain poorly understood.
Whole genome sequencing offers a comprehensive approach for identifying sequence
variants that confer drug resistance, but this technology does not assess the complex
interaction of multiple genomic, transcriptomic and epigenetic mechanisms.187 In the
current study, we integrated genome-wide interrogation of multiple genomic and
epigenetic features of primary leukemia cells to identify genes associated with drug
resistance, using glucocorticoids as a model. This directly identified over 78% of genes
and 100% of pathways previously associated with glucocorticoid resistance and further
revealed 14 genes not previously known to confer glucocorticoid resistance. Collectively,
this represents an agnostic, multi-dimensional genome-wide strategy for discovery of
genomic mechanisms of drug resistance in primary cancer cells.
Results
Drug Sensitivity and Treatment Response
The sensitivity to prednisolone of primary leukemia cells from bone marrow
aspirates of 225 newly diagnosed patients with B-lineage ALL ranged over 5 orders of
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magnitude (LC50 0.00176 -1387.4µM) (Figure 4-1a).
Using previously reported criteria, patients with prednisolone LC50 values <0.1
µM were classified as sensitive, those >64 µM were classified as resistant, and the
remaining patients were designated as intermediate sensitivity.75 Patients whose leukemia
cells were intermediate or resistant to prednisolone were significantly more likely to have
minimal residual disease (MRD) >1% at day 15-19 of remission induction therapy (p=1.3
x10-5; Figure 4-1b). Likewise, MRD at the end of remission induction therapy, on day 46
of St. Jude Total XV protocol (TOTXV) or day 42 of St. Jude Total XVI protocol
(TOTXVI), was more likely to be >0.1% in patients whose leukemia cells were
intermediate or resistant to prednisolone (p=1.1 x10-4; Figure 4-1b). These MRD levels
have been previously associated with a significantly worse event free survival.188-190
Polygenomics of Glucocorticoid Resistance
Six distinct genomic/epigenetic features were interrogated genome-wide in
primary leukemia cells and assessed for their association with prednisolone resistance
(LC50) in two independent patient cohorts [Figure 4-2]. Hierarchical clustering of each
feature type was performed to identify genomic features (mRNA, miRNA, CpG
methylation, single nucleotide polymorphisms [SNPs], copy number alterations [CNAs]
and SNV/Indels [WES]) that best discriminated prednisolone sensitive and resistant ALL
(Supplementary Table 1). These analyses identified 254 mRNA expression probes
(permutation p-value < 8.2x10-5), 203 CpG methylation sites (permutation p-value <
1x10-5 ), 49 miRNA probes (permutation p-value < 1x10-5), 380 SNPs (permutation pvalue< 1x10-5), 25 CNA segments (permutation p-value < 4.5x10-4) and 227 WES
mutations (permutation p-value < 1x10-5 ) that best individually discriminated
prednisolone resistant from prednisolone sensitive ALL (Figure 4-3; Figure 4-4a-b;
Supplementary Table 1). This mRNA expression signature was verified in two
independent validation cohorts (Figure 4-4c-d). Collectively, these features identified
192 distinct genes associated with prednisolone resistance.
Connectivity of these genomic features (miRNA, methylation, SNPs, CNAs and
SNV/Indels) was initially assessed based on significant relation to mRNA expression and
filtered based on biologically relevant criteria (cis CpG site or miRNA binding site as
described in Methods), revealing that the expression of 94% of the significant mRNAs
was significantly associated with at least one of the other genomic features and five were
connected to all other features (IDI1,ITPR3, PTPRF, WNK1, and PAX5; Supplementary
Table 2). mRNA expression probes that were associated with LC50 in the polygenomic
analysis were also associated with treatment response, as assessed by the in vivo level of
residual leukemia on day 15-19 and day 42-46 of remission induction treatment (Figure
4-4e). Prednisolone LC50 across all subtypes revealed some ALL subtypes that were more
resistant than others, but prednisolone resistant and sensitive cases were documented in
all major subtypes (Figure 4-4f)
Genes identified in the polygenomic analysis (Figure 4-3) were interrogated for
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Figure 4-1. De novo sensitivity of primary leukemia cells to prednisolone and
clinical treatment response
a) Distribution of prednisolone LC50 values in the discovery cohort, comprising children
with acute lymphoblastic leukemia enrolled on two consecutive research protocols at St.
Jude (n=119 and n=106 ALL patients, respectively) depicting >10,000- fold range in ex
vivo sensitivity. Horizontal dashed lines depict LC50 values discriminating prednisolone
sensitive, intermediate and resistant cases using previously reported values.75 b) The
percentage of patients who had minimal residual disease (MRD) in their bone marrow at
day 15-19 of treatment (MRD ≥ 1%) or at day 42-46 of treatment (MRD ≥0.1%) differed
significantly based on prednisolone sensitivity (Chi-Square test p-value; n=221 ALL
patients).
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Figure 4-2. Polygenomic analysis workflow
(a.) Flowchart depicting cohorts, genomic assays and detailed analysis pipeline for
polygenomic analyses of multiple feature types (mRNA, miRNA, DNA methylation,
SNVs, CNVs and WES mutations) as determinants of prednisolone sensitivity in patients
diagnosed with acute lymphoblastic leukemia (“lm” = linear model). (b.) Table
describing age, race, gender and molecular subtype of discovery cohort (n=225 patients)
from polygenomic analysis. The P-values represent differences between the discovery
cohort enrolled on the two clinical trials (Fisher’s Exact Test p-value; Total 15 and Total
16).
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Figure 4-3. Polygenomic analyses identify genomic features related to
prednisolone resistance
Leukemia cell mRNA, miRNA, DNA methylation, copy number alterations (CNAs),
single nucleotide polymorphisms (SNPs) or coding SNVs/Indels (by WES) that
significantly discriminate prednisolone sensitive and resistant ALL, by hierarchical
clustering in the discovery cohorts (TOTXV and TOTXVI). Each column represents an
individual patient’s ALL cells, those labeled at the top with green are sensitive and those
with red are resistant to prednisolone; each row indicates a different probe. (Center panel)
mRNA expression vs prednisolone LC50: heat map depicts high (red) or low (blue) gene
expression relative to the mean signal for that probe set in the entire cohort [n=254
mRNA probes; n= 203 patients]. (Top left) heat map for miRNA expression versus LC50;
red and blue denote higher versus lower expression relative to mean signal for probe
amongst the entire cohort [n=49 miRNAs; n=163 patients]. (Top Right) DNA
methylation versus LC50; red and blue denote higher versus lower methylation signal
[n=203 CpG probes; n=178 patients] (Bottom left) single nucleotide polymorphisms
(SNPs) associated with LC50 blue = AA, orange = AB, purple = BB [n=380 SNPs; n=184
patients]. (Bottom right) copy number alterations (CNAs) associated with LC50; red =
copy gain, blue = copy loss, orange = copy neutral [n=25 CNAs; n= 184 patients].
(Bottom center) SNVs and Indels by WES [n=227 SNVs/Indels] associated with LC50;
purple = mutation, orange = non-mutated. (Lines) lines connecting probe sets are drawn
where significant associations were found between mRNA expression levels and a
specific peripheral genomic feature. DNA methylation and miRNA connections were
required to be significantly negatively associated with mRNA expression; DNA
methylation probes were also required to be within 100kb of the gene encoding the
mRNA and miRNAs were required to have a predicted binding site in the gene and/or
experimental evidence from literature. Connections between SNVs/Indels and mRNA are
provided in Figure 4-4a. P-values for each heatmap (at top) indicate the results of
Fisher’s exact tests comparing the distribution of sensitive and resistant cases when the
highest level of the dendrogram is split in two. Overall clustering P-values for each
heatmap (at bottom) are the result of Stouffer’s meta-analysis of corresponding individual
Fisher’s exact test (two-sided) p-values within each cohort.
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Figure 4-4. Validation of gene expression signature, relation to treatment
response and WES variant connectivity
(a.) Connectivity between polygenomic signatures for mutation (n=227 mutations) and
mRNA expression (n=254 mRNA probes; Fisher’s Exact Test clustering p-values and
linear model p-value for connectivity). (b.) Characteristics of WES mutations with linear
model p-value <0.05 vs. LC50. (SIFTcat Del = Deleterious and Tol = Tolerated). (c.)
RNA sequencing of ALL cells from St. Jude Total XVI patients (n=73 patients;
validation cohort #1; Fisher’s Exact Test clustering p-value) clustered with gene
expression signature from discovery cohort analysis. (d.) Publicly available
DCOG/COALL patient cohort (n=145 patients; validation cohort #2; Fisher’s Exact Test
clustering p-value) clustering with gene expression signature from patient discovery
cohort. (e.) Clustering of gene expression vs. LC50. Red denotes genes correlated with
LC50 or minimal residual disease (MRD) in positive direction. Blue denotes genes
correlated in negative direction with LC50 or MRD. Clustering performed to show
concordance of genes discriminating LC50 or MRD. (f) Boxplot denoting Prednisolone
LC50 in patients from discovery cohort with the major ALL molecular subtypes. Red
circles denote prednisolone resistant patients, green denotes sensitive patients, and black
denotes intermediate sensitivity. Upper line is the upper quartile (75%) middle line is the
median and lower line is lower quartile (25%) boundary for prednisolone LC50.
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relevant pathway connections (Supplementary Table 3), that included B-cell
development (PAX5 mRNA, FLT3 methylation and SNV/Indel, ITGA4 SNP eQTL) , Bcell receptor signaling (e.g., CD19 methylation, PAX5 mRNA, TCF3 mRNA), noncanonical Wnt signaling (CELSR1/2 methylation and mRNA, ROR1 mRNA), IL7Rsignaling (e.g., IL2RG mRNA, JAK3 SNP eQTL), SWI/SNF complex (SMARCA4
mRNA), TGF-B signaling, apoptosis signaling (BCL2 methylation, FAS mRNA), drug
transporters (ABCC1 methylation), and inflammatory signaling (CASP1 methylation and
mRNA, NLRP3 methylation).
Gene Level Integration of Multiple Genomic Variants
To assess the influence of each gene on prednisolone resistance, we aggregated pvalues of all genomic features within 50 kilobases upstream or downstream of the coding
region for all annotated human genes (n = 19,725), to obtain a gene-level TAP (Truncated
Aggregation of P-values) statistic with its associated p-value (see Methods). This
identified 903 genes associated with prednisolone resistance (p<5.38x10-4; Figure 4-5a;
Supplementary Table 4). Figure 4-6 illustrates four gene-level plots and their TAP
statistic. SMARCA4 and NLRP3 illustrate genes previously associated with prednisolone
resistance,75,123 whereas CELSR2 and PTTG1IP illustrate the top two novel genes in
current study (Figure 4-6; Supplementary Table 5). Many of these genes, 118/463
(25%), are common between the gene-level TAP analysis and the polygenomic analysis
that assessed each feature independently (Figure 3c). Pathway analysis of genes
significant in the TAP analysis is detailed in Supplementary Table 3.
Validation by Genome-wide CRISPR Knockout Screen
To validate hits by an orthogonal method, we performed genome-wide
CRISPR/Cas9 knockout screening using the GeCKOv2 library.157 In cells treated with
100uM prednisolone, we identified 1024 genes that were significantly “knockout
enriched” in prednisolone resistant leukemia cells (FDR < 5.2x10-7; Figure 4-5b;
Supplementary Table 6). NR3C1, the gene encoding the GR, was the top “knockout
enriched” gene (p= 4.6x10-78). This screen identified genes affecting multiple cellular
functions, including several pro-apoptotic genes (BAK1, PMAIP, APAF1, CAPN3/10)
and genes involved in GR signaling, cell-cell communication genes (ITGA5/B1,CELSR2),
modulators of GR transcriptional activation (NRIP1, JUN), inhibitors of NF-kB kinase
(IKBKB, IKBKG), B-cell developmental genes (BCL6), glucocorticoid biosynthetic
components (HSD3B1/7, CYP11B1), cytokine signaling genes (e.g.,IL4R, IL1RAPL2),
toll-like receptor signaling (TLR6, IRAK3, TNF), inhibitors of PI3K signaling genes
(PTEN), and other genes previously associated with glucocorticoid resistance (TBL1XR1
and CNR2). When the knockout enriched genes were used to perform clustering on the
RNA-seq from a 320 patient validation cohort, this significantly discriminated resistant
and sensitive leukemias (clustering p- value = 0.006).
We also identified 1000 genes that were significantly “knockout reduced” (i.e.
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Figure 4-5. Genomewide orthogonal validation identifies CELSR2 as a key
mediator of glucocorticoid resistance
(a.) Manhattan plot of gene-level aggregated p-values (TAP statistic) for all 19,725 genes
(n= 203 patients) (illustrated in regional plots for four genes in Figure 4-6). Circles
above the blue dotted threshold line represent genes only significant in TAP analysis,
squares depict genes significant in both the TAP and CRISPR screen, triangles represent
genes significant in both the polygenomic analysis and the TAP analysis, and red stars
depict the 15 genes significant in all three analyses (linear regression p-value cutoff
[adjusted for massive multiple testing by adaptive thresholding] = 5.38x10-4). (b.) -log10
p-values for genes (n=19,050 genes in two replicate experiments) interrogated in the
CRISPR knockout screen (“knockout enriched”). The threshold for statistical significance
(logit gene-level one-sided p= 4.0x10-8 [FDR adjusted p = 5.2x10-7]) of association with
prednisolone resistance is depicted by the horizontal dotted line. (c.) Venn diagram
showing overlap among genes significant in each analysis with 15 genes significant in all
three analyses. (d-e) CELSR2 mRNA expression in leukemia cells from newly diagnosed
patients enrolled on St. Jude clinical trials, grouped based on prednisolone sensitivity
(LC50) in (d.) the discovery cohort (n=203; linear model p-value) and (e.) an independent
validation cohort (n=320; linear model p-value). (f-g) NR3C1 mRNA expression in
leukemia cells from newly diagnosed patients enrolled on two St. Jude clinical trials,
grouped based on CELSR2 expression (low ≤ lower quartile, high ≥ upper quartile and
intermediate falls between the upper and lower quartile of CELSR2 expression) in (f.) the
discovery cohort (n=203; linear model p-value) and (g.) an independent validation cohort
(n=320; linear model p-value). (h.) Representative western blot and bar graph quantifying
(n=3 biologically independent experiments) knockdown of CELSR2 (mean ± SD) in two
human B-lineage leukemia cell lines (NALM-6 two tailed t-test p-value = 0.0026 and 697
two-tailed p-value = 0.0081; ** = <0.01; cropping performed uncropped image available
as source data). (i.) Prednisolone LC50 values in human ALL cells lines (NALM-6 and
697) expressing CELSR2 shRNA (~70% knockdown) or non-target control (results of
triplicate experiments). For all boxplots, horizontal bars depict medians and boxes
represent 25th and 75th percentiles, whiskers represent ±1.5x interquartile range (IQR);
p-values are two-tailed t-test).
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Figure 4-6. Gene level integration of genomic variants related to prednisolone
resistance
Each panel depicts -log10 p-values for the association of the indicated genomic feature
with prednisolone LC50, and the aggregated gene-level linear model p-value based on all
genomic features is shown for each gene at the top right. Red triangles represent mRNA
probes within the gene body, orange diamonds depict copy number variants, blue squares
are DNA methylation probes, grey circles SNVs, and purple circles miRNAs within 50kb
upstream or downstream of gene region (n=203 patients). (a.) SMARCA4, a component of
the SWI/SNF complex, has been previously linked to glucocorticoid resistance in
pediatric ALL.123 (b.) NLRP3 encodes NALP3, an inflammasome component that
activates caspase 1, and has been previously associated with ALL resistance to
glucocorticoids.75 (c.) PTTG1IP encodes the pituitary tumor-transforming gene 1 proteininteracting protein that interacts with the proto-oncogene PTTG1 (also known as securin).
(d.) CELSR2 is a G-protein coupled receptor involved in non-canonical Wnt signaling.
PTTG1IP and CELSR2 are novel genes from the current study associated with
glucocorticoid resistance.
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depletion of gRNAs targeted to knockout these genes, FDR < 1.19x10-14;
Supplementary Table 6), suggesting their absence enhanced glucocorticoid sensitivity.
This revealed genes associated with various signaling pathways such as inflammasome
activation (NLRP3, NLRC3, CARD11/17), NF-kB signaling (NFKB2, NFKBIB),
JNK/SAPK signaling (e.g., MAPK9[JNK2], RAC2), PI3K signaling (PI3KR1/3, PI3KR3,
PRKCB), apoptotic proteins (FAS), TNF signaling and growth factor signaling (FGFR2,
FGF10) [Supplementary Table 3]. The knockout reduced genes were also able to
discriminate glucocorticoid resistant and sensitive leukemias in the 320 patient validation
cohort (clustering p-value = 1.7x10-5).
Genes Significant by Multiple Methods
As summarized in Figure 4-5c, 247 genes were significant by at least two
methods and significantly discriminated resistance in the 320 patient validation cohort
(clustering p-value = 0.001), as did the 118 genes significant by both TAP and
polygenomic analyses (clustering p-value = 1.34x10-6), and the 50 genes in both CRISPR
and the polygenomic analysis (clustering p-value = 6x10-4). Fifteen genes (CELSR2,
MAPK13, PARD3, CALN1, DAP, RBMS2, PTTG1IP, NLRP3, FAM13A, TAOK3,
DCLRE1A, RASGRF2, FBXO9, GALNT1 and TMEM126A) were significant by all three
methods, thereby constituting the top candidate genes (Figure 4-5c; Supplementary
Table 5), and they discriminated sensitive from resistant leukemias in the validation
cohort (clustering p-value = 1x10-4). Only one of the 15 top candidate genes (NLRP3) has
been previously associated with glucocorticoid resistance.75 The statistical likelihood of a
gene being significant by all three methods by chance is very low (p = 8.2x10-79).
Corroboration of Known Resistance Mechanisms
To assess the robustness of our approach, we compared genes/miRNAs that were
significantly related to glucocorticoid resistance in our analyses, to genes involved in
previously published mechanisms of glucocorticoid resistance (35 genes and three
miRNAs, identified as described in Methods, summarized in Supplementary Table 7).
Of these 38 previously reported genes/miRNAs, 30 (79%) were found to be significant by
one or more of our three methods. This improved to 38/38 (100%) genes/miRNA when
we included other members of the involved resistance pathway using StringDB (strict
criteria as defined in Chapter 3).
CELSR2 Knockdown Alters Transcriptional Response and Prednisolone Resistance
CELSR2 was the top novel candidate gene by all three methods, with decreased
expression associated with glucocorticoid resistance in the discovery cohort (p= 3.3x1010
; Figure 4-5d; Supplementary Table 5). CELSR2 remained significant after adjusting
for leukemia molecular subtype (p < 9.5x10-6). Lower CELSR2 expression in
glucocorticoid resistant ALL was subsequently validated in primary leukemia cells from
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two independent validation cohorts, one comprising 320 pediatric and adult patients with
newly diagnosed ALL (p= 8.3x10-8; Figure 4-5e), and the other comprising 145 pediatric
patients with newly diagnosed ALL (p= 0.033). We also documented in primary
leukemia cells that patients with low expression of CELSR2 (defined as mRNA ≤ the
lowest quartile of expression) had significantly lower expression of the GR (NR3C1;
Figure 4-5f,g; p-value= 1.7 x10 -4). We also observed 5 patients with copy number
alterations in CELSR2, and 4 were resistant to glucocorticoids. Only two patients had
predicted damaging missense mutations in CELSR2, one was prednisolone resistant and
the other prednisolone intermediate sensitivity. Reduction of CELSR2 expression in two
human ALL cell lines by shRNA (Figure 4-5h), significantly increased prednisolone
resistance (LC50) compared to non-targeting control (Figure 4-5i). There was a 12.7-fold
increase in LC50 in CELSR2 knockdown NALM-6 cells (0.026 ± 0.033µM vs 0.37 ± 0.1
µM (mean ± s.e.m), p=7.8x10-5), and a 20-fold increase in LC50 in 697 cells
(0.095±0.003 µM vs. 1.98±0.046 µM (mean ± s.e.m), p=9.0x10-4).
To assess the mechanism of GC resistance, we identified differentially expressed
genes and alterations in global transcriptional effects of glucocorticoids in CELSR2
knockdown cells. Knockdown of CELSR2 led to a significant decrease in basal
expression of the GR (NR3C1) in both NALM-6 cells (1.8-fold decrease; p= 1.34x10-7;
Figure 4-7a), and 697 cells (1.3 fold-decrease, p= 4.3x10-5; [Figure 4-8a]). Decreased
expression of total cellular GR in CELSR2 knockdown cell lines was more prominent
after 24 hours of prednisolone treatment in the NALM-6 cell line (2.3-fold decrease; p =
2.8x10-12; Figure 4-7b), and in the 697 cell line (1.44 fold-decrease; p= 1.45x10-5;
[Figure 4-8b]). A second shRNA was used to confirm on-target specificity and
phenotype (Figure 4-8c). Stable CELSR2 protein knockdown (Figure 4-8d) showed
decreased glucocorticoid receptor protein expression (Figure 4-8e) in ALL cells. Stable
re-expression of GR (97% of control) significantly re-sensitized leukemia cells to
prednisolone (Figure 4-7c-d; two-tailed t-test p-value = 0.02).
After activation of the GR with 24 hours of glucocorticoid treatment, many genes
were differentially expressed in CELSR2 knockdown versus control ALL cells, including
a robust upregulation of the antiapoptotic gene BCL2 in CELSR2 knockdown cells,
documented at the transcriptional (2.5-fold increase; p= 3.7x10-12; Figure 4-7b) and
protein level (1.3-fold increase; p = 0.0128; Figure 4-8f), consistent with the known
repressive effect of activated GR on BCL2.191 BCL2L11 (Bim), a pro-apoptotic gene
known to be up-regulated by glucocorticoids192 did not exhibit upregulation in CELSR2
knockdown cells after 24 hours of prednisolone treatment (1.3-fold decrease, compared
to a 1.8-fold increase in non-targeting control p= 4.6x10-6; Figure 4-8g), yielding a lower
ratio of BIM/BCL2 protein expression in the CELSR2 knockdown NALM-6 cells after 24
hours of prednisolone treatment. (Figure 4-8h). Genome-wide analysis of glucocorticoidinduced gene expression changes in NALM-6 cells (3 replicate experiments) identified
415 genes that were induced at least three-fold compared to untreated cells, 72%
(298/415) of which had lower induction (at least 25% less induction) by prednisolone
treatment in CELSR2 knockdown cells, consistent with lower GR (Figure 4-7e).
Furthermore, 69 genes were repressed by at least three-fold in control cells, and 90%
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Figure 4-7. CELSR2 knockdown decreases GR expression and attenuates
glucocorticoid modulation of gene expression
(a.) Volcano plot (n= 3 independent experiments) for untreated CELSR2 knockdown
human leukemia cell line (NALM-6) vs. non-target control (NTC). Left side of plot
depicts genes with reduced expression in CELSR2 knockdown cells and genes to the right
exhibiting increased expression in CELSR2 knockdown cells. Orange and red symbols
depict mRNAs with significant changes in expression (linear model p-value); red
symbols have a fold change greater than 2. (b.) Volcano plot of gene expression after 24
hours of 10µM prednisolone treatment of CELSR2 knockdown vs. non-target control
ALL cells (NALM-6, n=3 independent experiments; linear model p-value). (c.) (left)
NR3C1 protein quantification (n= 2 independent experiments) or (right) Prednisolone
LC50 (n=3 independent experiments; mean ± SD) in Nalm6 NTC or shCELSR2 cells with
either GFP control or re-introduction of NR3C1 (two tailed t-test p-value; * =p < 0.05 ,**
= p <0.01, *** = p <0.001). (d.) Representative western blot of GR protein expression
(n= 2 independent experiments) in NTC or shCELSR2 NALM-6 cells with or without
GR re-expression. (e.) The 75 most highly upregulated (top) or downregulated (bottom)
genes in human NALM-6 ALL cells after 24 hours treatment with 10µM prednisolone
(n= 3 independent experiments). Blue and green bars depict mRNA expression in
NALM-6 cells transfected with non-target control vector and gold bars depict blunted
induction or repression in cells expressing shRNA for CELSR2 knockdown (mean ± SD).
(Inset) Representative western blot (n= 3 independent experiments) showing significantly
lower GR levels in CELSR2 knockdown cell lines compared to non-targeting controls,
with or without prednisolone treatment for 24hr (cropping performed uncropped image
available as source data).
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Figure 4-8. CELSR2 knockdown blunts glucocorticoid responsiveness of 697 cells
and increases sensitivity to venetoclax
(a.) Volcano plot for untreated CELSR2 knockdown ALL cell lines vs. non-target control
in 697 cell line (n= 3 independent experiments; linear model p-value). Left side of plot
depicts genes with reduced expression in CELSR2 knockdown cells and genes to the right
had increased in expression in CELSR2 knockdown cells. (b.) Volcano plot of gene
expression after 24 hours of prednisolone treatment of CELSR2 knockdown vs. nontarget control ALL cells (697; n= 3 independent experiments; linear model p-value). (c.)
Dose-response plot (mean ± S.D.; n= 3 independent experiments) of two shRNA
constructs vs non-targeting control and un-transduced NALM6 leukemia cell line. (d.)
CELSR2 (n= 3 independent experiments) (e.) NR3C1 (n= 3 independent experiments) (f.)
BCL2 (n=5 independent experiments) (g.) BIM (n= 4 independent experiments) and (h.)
Bim/Bcl2 protein expression (mean ± S.D; n=4 independent experiments; two-tailed ttest p-values; * =p < 0.05 ,** = p <0.01, *** = p <0.001, **** = p <0.0001) in Nalm6
cells comparing controls (NTC; solid bars) to CELSR2-knockdown (shCELSR2) either
prior to prednisolone treatment (0HR) or after 24hr prednisolone treatment (24HR). (i.)
The 75 most highly upregulated (top) or downregulated (bottom) genes after 24 hours
treatment with 10µM prednisolone. Blue and green bars depict mRNA expression (mean
± S.D.; n= 3 independent experiments) in 697 cells transfected with non-target control
vector and gold bars depict cells expressing shRNA for CELSR2 knockdown.
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(62/69) had at least 25% lower repression in CELSR2 knockdown cells (Figure 4-7e;
Supplementary Table 8). Similar results were observed in the 697 cell line (Figure
4-8i).
Mitigation of Glucocorticoid Resistance Caused by Low CELSR2 Expression via
Inhibition of BCL2
Because the anti-apoptotic gene BCL2 was highly induced in CELSR2 knockdown
cells after prednisolone treatment, we tested venetoclax (a BCL-2 inhibitor) for its ability
to mitigate glucocorticoid resistance in ALL cells with low CELSR2 expression. When
CELSR2 knockdown ALL cells were treated for 72 hours with prednisolone (0.954nM 4mM) and varying concentrations of venetoclax, synergy was evident in two human
leukemia cell lines (NALM6 α =2.07; 697 α =2.47; Figure 4-9a.; Figure 4-10a,c), but
synergy was greatly increased in leukemia cells in which CELSR2 was knocked down
(NALM-6 α = 5.22; 697 α = 4.38; Figure 4-9b;Figure 4-10b,d), and confirmed using
other methods for assessing drug synergy (Loewe’s additivity and ZIP method; data not
shown).
In mice inoculated with NALM-6 leukemia cells with shRNA targeting CELSR2,
there was a significant prolongation of survival in mice treated with venetoclax 50 mg/kg
plus dexamethasone, compared to dexamethasone alone (median survival 60 vs 69 days;
p=0.0062; Figure 4-9d) or venetoclax alone (median survival 56 vs 69 days; p=0.0046;
Figure 4-9d). In mice inoculated with NALM-6 leukemia cells with the non-targeting
control shRNA (NTC), there was modest but significant prolongation of survival when
treated with venetoclax 100 mg/kg plus dexamethasone compared to dexamethasone
alone (median survival 39 vs 41 days; p=0.02; Figure 4-9c), whereas there was not
significant improvement with the lower dosage of venetoclax (50 mg/kg) combined with
dexamethasone (p=0.836; Figure 4-9c), consistent with greater synergy in ALL with
lower CELSR2 expression.
To verify these findings in primary leukemia cells, we documented that primary
leukemia cells (n= 96 patients) that were resistant to prednisolone were significantly
more sensitive to venetoclax (p=0.014; Figure 4-10e). As reported for other
malignancies,193,194 higher BCL-2 expression in primary ALL cells was associated with
increased sensitivity to venetoclax (p=2.5x10-3; Figure 4-10f).
We also measured the effects of the two drugs given separately or together in
primary leukemia cells isolated from the bone marrow or peripheral blood of six patients
(3 freshly isolated and 3 xenograft samples). In the two prednisolone sensitive patients,
we observed low levels of additivity/synergy, whereas in the four leukemias that were
intermediate or resistant to prednisolone, we documented greater synergy based on
significantly higher alpha values in all cases (Figure 4-10g). Three of the four
prednisolone resistant patients exhibited much lower mRNA expression of CELSR2 and
NR3C1 when compared to the prednisolone sensitive patients (Figure 4-10h), and
primary ALL cells from all four of the prednisolone resistant patients exhibited decreased
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Figure 4-9. Increased synergy and mitigation of glucocorticoid resistance by
inhibition of BCL2 in ALL with low CELSR2 expression
(a.) Response surface model (% Effect = % cell kill) depicting synergy between
prednisolone and Bcl-2 inhibitor venetoclax in NALM-6 cells transduced with non-target
control or (b.) CELSR2 knockdown ALL cells (n= 3 independent experiments; response
surface model two-tailed t-test p-value). The (α) value indicates antagonism < 0 or
synergy > 0, with higher values representing greater synergy. P-value assesses overall
model fit. (c.) Percent survival of NSG mice inoculated with 100,000 NALM-6 nontarget control cells or (d.) 100,000 CELSR2 knockdown leukemia cells treated with either
vehicle, dexamethasone alone (4 mg/kg), venetoclax alone (50 or 100 mg/kg) or
combination of venetoclax with dexamethasone (n= 5 mice per treatment group; Logrank Mantel-Cox test p-values).
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Figure 4-10. Venetoclax and prednisolone synergize in primary ALL with low
CELSR2 expression and CELSR2 knockdown in cell lines disregulation of Bim/Bcl2
axis
(a.) Response surface model plot of cytotoxicity from prednisolone plus venetoclax at
concentrations indicated for the 697 leukemia cell line transduced with non-targeting
control vector. (b.) Response surface model plot for the 697 leukemia cell line transduced
with CELSR2 shRNA knockdown vector (for a and b individual points represent n= 3
independent experiments performed in technical duplicate; response surface model twotailed t-test p-value). The alpha (α) value indicates antagonism < 0 or synergy > 0 with
greater synergy from higher value. P-value describes overall model fit. Individual plots of
prednisolone effect (mean ± S.D.; n= 3 independent experiments) (c.) NALM-6 and (d.)
697 leukemia cell lines at one concentration of venetoclax (mean ± S.D.; n= 3
independent experiments). Black lines are non-targeting control cells and red lines are
CELSR2 knockdown cells, dashed lines indicate predicted additivity curve fit based on
single drug treatments; data left of the dashed lines represent additivity/synergy. Solid
lines represent fit of measured values. (e.) Venetoclax sensitivity of independent cohort
of patients (n=96 ALL patients) grouped based on prednisolone sensitivity (LC50) (f.)
Bcl2 expression associated with sensitivity to venetoclax (n= 81 ALL patients) (g.)
Primary ALL cells from patients (n=6 patient samples) and human leukemia cell lines
assessed for additivity/synergy with prednisolone and venetoclax (for all box plots
horizontal bars depict medians and boxes represent 25th and 75th percentiles, whiskers
represent ±1.5x IQR; linear model p-values).(h.) mRNA expression (n=1 experiment run
in technical triplicate) of CELSR2 in patient samples assessed for synergy.
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ability to induce the pro-apoptotic protein BIM when treated with 10µM prednisolone for
24 hours (data not shown).
CELSR2 Is a Negative Hub Driver of Prednisolone Resistance
We used NetBID,169 a data-driven systems biology approach, to reconstruct a BALL-specific interactome (B-ALLi),composed of “hubs” representing central
components of larger regulatory networks, using RNA-seq profiles of 185 B-ALL
patients in the TARGET170 cohort (Figure 4-11a). B-ALLi identified hub drivers whose
network activities differed significantly in prednisolone resistant versus sensitive
leukemia cells from two patient cohorts (SJCRH TOTXV and TOTXVI; Figure 4-11b).
Known glucocorticoid resistance genes including SMARCA4, PAX5, CASP1 were
significantly enriched in NetBID top predictions (p=0.011, Figure 4-12a). Network
topology analysis of the top 48 NetBID drivers (p<5 x10-5, Figure 4-11b; Figure 4-12b)
identified CELSR2 as a hub that modulated other top drivers (Figure 4-11c). NetBIDinferred activity of CELSR2 was markedly down-regulated (p=8.6 x10-8; Figure 4-11d)
in prednisolone resistant relative to sensitive leukemias, as was the expression of
CELSR2 (Figure 4-11b). More strikingly, CELSR2 regulons (Figure 4-12c) inferred by
NetBID from baseline RNA-Seq profiles of B-ALL patients were significantly enriched
among differentially expressed genes in ALL cells after CELSR2 knockdown (p=1 x10-4
in NALM-6 and p=1 x10-3 in 697 cells, Figure 4-11e; Figure 4-12d). Several previously
reported glucocorticoid resistance genes (e.g. TSC22D3, IL1B and TP53INP1), were also
regulated by CELSR2 (p=1.8 x10-3 in NALM-6 and p=0.01 in 697; Figure 4-12e).
CELSR2 Expression Is Significantly Related to PAX5
NetBID analysis also identified CELSR2 as a top downstream target of PAX5
(Figure 4-13a). For CELSR2, the most highly co-expressed gene in primary ALL cells
was PAX5, which was highly positively correlated in leukemia cells from 203 patients
(p= 3x10-11; Figure 4-13b). Accordingly, lower expression of PAX5 was observed in
leukemia cells with higher prednisolone LC50 (p = 7.47x10-5; Supplementary Table 1).
Recent studies have highlighted the importance of chromatin accessibility in the
discovery of novel regulators of glucocorticoid resistance.94,98 ATAC-seq profiles of
multiple human leukemia cell lines revealed open chromatin regions in proximity to the
CELSR2 coding region. When combined with ENCODE transcription factor binding site
data,147 PAX5 binding sites were found within the cis-regulatory elements of CELSR2 in
the B-lymphocyte cell line GM12878 (Figure 4-13c). Furthermore, CHIP-seq peaks for
PAX5 in NALM-6 ALL cells confirmed that PAX5 binds in these open chromatin regions
in a leukemia cell line (Figure 4-13c). We constructed a multivariate model using the
expression of all miRNAs associated with CELSR2 as co-variates along with PAX5
mRNA, revealing that PAX5 expression accounted for about 25% of the variability in
CELSR2 expression (p= 1.6x10-12), and mir-31-5p accounted for an additional 4% of the
variability in CELSR2 expression (p=0.002). Alone, miR-31-5p was significantly
negatively associated with CELSR2 expression (p= 0.001), as was PAX5 (p=3x10-11).
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Figure 4-11. NetBID identifies CELSR2 as a hub driver of prednisolone resistance
(a.) Schematic workflow representing NetBID algorithm (b.) Heatmap of top 48 NetBIDpredicted drivers from total of n=7,920 drivers inferred from the B-ALL interactome
(n=185 patients) that were associated with prednisolone resistance (n=203 patients with
gene expression and LC50). Drivers (as denoted by “symbol_regulon size”, e.g
“CELSR2_399”) are ranked by integrated NetBID p-value. (Left) Combined NetBID
results color-coded by z-score (red = positive, blue = negative) and labeled by p-value of
integrated NetBID results of TOTXV and TOTXVI patient cohorts; Right: differential
expression (DE) of each driver itself, color-coded by z-score and labeled by signed foldchange of integrating the two cohorts (shown separately in Figure 4-12). (c.) Subnetwork
of the top 48 drivers versus prednisolone LC50 in relation to one another (limited to top
50 interactions for each driver ranked by mutual information of each hub gene) from BALLi. Node size is proportional to the regulon size; nodes in green represent known
resistance genes. Edges: width is proportional to mutual information, red is for positive
and blue for negative Spearman correlations of the connecting nodes. (d.) CELSR2
NetBID activities (horizontal bar depicts median and boxes represent 25th and 75th
percentiles, whiskers represent ±1.5x IQR) in prednisolone resistant and sensitive patients
from TOTXV and TOTXVI patient cohorts (Stouffer’s combined Bayesian generalized
linear model “NetBID” p-value; n=203 patients). (e.) Enrichment of NetBID-inferred
CELSR2 regulon (n= 399 genes) in differentially expressed genes (n= 222 genes) of
CELSR2 knockdown vs. control in NALM-6 (top) and 697 (bottom) cell lines without
prednisolone treatment.

64

65

Figure 4-12. NetBID identifies regulatory nodes of prednisolone resistance
(a.) Enrichment of previously reported resistance genes (n=40 genes and miRNAs;
Wilcoxon two-tailed p-value) in NetBID results. (b.) Heatmap of top 48 NetBIDpredicted drivers (‘symbol’_’regulon size’) are ranked by integrated NetBID p-value.
Left: color-coded by z-score and labeled by p-value of NetBID results in TOTXVI,
TOTXV, and combination (Comb); Right: differential expression of each driver itself,
color-coded by z-score and labeled by signed fold-change in TOTXVI, TOTXVI and
combination (Comb; Stouffer’s combined Bayesian generalized linear model “NetBID”
p-value; n=203 patients). (c.) CELSR2 regulon from B-ALLi (n=399 genes). Legends of
node and edge follow Figure 4-11c. (d.) Enrichment of NetBID-inferred CELSR2
regulon (n=399 genes) in differentially expressed genes of CELSR2 knockdown vs. NTC
in NALM-6 human ALL cell lines (n=222 genes; Wilcoxon two-tailed p-value) upon
prednisolone treatment for 24hr (top) Blue lines inside the box indicate the downregulation of CELSR2 itself, labeled p-value and signed fold-change. (e.) Enrichment of
previously reported resistance genes (n= 40 genes and miRNAs; Wilcoxon two-tailed pvalue) in differentially expressed genes of CELSR2 knockdown vs. NTC in NALM-6
ALL cell lines without prednisolone treatment.
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Figure 4-13. CELSR2 mRNA expression is related to PAX5 expression in primary
ALL cells
(a.) Subnetwork (top 50 interactions ranked by mutual information) of PAX5 and
CELSR2 from B-ALLi (n=185 patients). Legends of node and edge follow Figure 4-11c,
except that nodes in green are those in top 48 drivers (Figure 4-11b). (b.) CELSR2
expression positively correlates with PAX5 expression in primary acute lymphoblastic
leukemia cells (black line represents regression fit associated with linear model p-value
and Rsq). (c.) Open chromatin regions defined by ATAC-seq in three sensitive and three
resistant human leukemia cell lines and H3K27 acetylation from ENCODE in upstream
5’ region of CELSR2. ENCODE binding site in GM12878 lymphoid cells for PAX5 and
CHIP-seq peaks from NALM-6 cells for PAX5 binding are indicated at bottom of the
plot. (d) PAX5 (**** = 3.5x10-5) (e.) CELSR2 (*** = 3.0x10-4) (f.) NR3C1(**** =
3.2x10-5) protein expression (mean ± S.D.) in NALM-6 leukemia cell lines stably
expressing shRNA knockdown constructs targeting PAX5 (n=4 independent experiments;
two-tailed t-test p-values).
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PAX5 knockdown in NALM-6 cells (Figure 4-13d) showed significant reduction in both
CELSR2 (two-tailed t-test p-value =0.0003; Figure 4-13e) and NR3C1 (two-tailed t-test
p-value<0.0001; Figure 4-13f).
scRNA-seq Reveals Clonality of Resistance Genes
We performed single cell RNA-seq on primary ALL cells from a patient with
prednisolone sensitive leukemia (LC50 = 0.091µM) and from a patient with prednisolone
resistant leukemia (LC50 = 1006µM). Primary leukemia cells from each patient were
treated ex vivo with 63µM prednisolone or incubated in media without prednisolone, and
single-cell RNA sequencing was used to generate clusters of surviving cells after 96
hours, based on their gene expression profiles. As expected, the prednisolone sensitive
leukemia had a pronounced reduction in CD19+ cells (Figure 4-14a,d; Figure 3-5a-c; p<
2x10-16), whereas the resistant leukemia retained a high percentage of CD19+ cells after
prednisolone treatment (Figure 4-14a; Figure 3-5d-f; Supplementary Table 9). Singlecell RNA sequencing documented that the sensitive leukemia had higher CELSR2
expression before treatment than the resistant leukemia, which had essentially
undetectable de novo expression of CELSR2 (Figure 4-14b; FDR = 0.009). BCL-2
expression was significantly higher in the resistant patient after prednisolone treatment
compared to control, and greater than in the sensitive leukemia (Figure 4-14c,f; FDR =
0.005; Supplementary Table 9).
CELSR2 Is a Mediator of Non-canonical Wnt Signaling
To assess the potential effects of CELSR2 on GR expression, we performed
ATAC-seq to interrogate regulatory regions upstream of the NR3C1 gene in three
glucocorticoid sensitive and three glucocorticoid resistant ALL cell lines, revealing
enriched open chromatin for the GR in the sensitive cell lines compared to resistant ALL
cells, in regions overlapping H3K27-acetylation peaks from ENCODE (Figure 4-15a-d).
The REH cell line has a known stop gain mutation in NR3C1, which leads to
glucocorticoid resistance independent of CELSR2. ENCODE transcription factor binding
data revealed binding sites for TEAD4 (Hippo signaling), NFATC1 and the AP-1
components cJun and fos within the upstream regulatory regions of NR3C1 (Figure 415d).
Because CELSR2 is known to regulate non-canonical WNT signaling,195 we
quantitated the expression of NFAT, pJNK, cJun, phos-cJun and NR3C1 in CELSR2
knockdown cells and control cells (Figure 4-16; Figure 4-15e-h). This documented
significantly lower nuclear expression of phosphorylated JNK (p=0.015) and lower
phosphorylation of its target cJun at serine 63 (p=0.0017), which was also evident in cells
treated with prednisolone (24hr at 10µM; p=0.03). We also documented decreased
nuclear GR levels in CELSR2 knockdown compared to control cells in both treated
(p=0.03) and untreated (p=0.005) cells. Cytoplasmic levels of the GR were also
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Figure 4-14. Single cell transcriptomic analysis verifies lower CELSR2 and higher
BCL2 in glucocorticoid-resistant primary ALL cells
(a.) Clustering of single cells (n= 2 patients) based upon the top 1000 most highly
expressed genes. Both patients are independent of the discovery and validation cohorts;
leukemia cells from one patient are sensitive (left) and one resistant to prednisolone
(right). Clusters annotated to show CD19+ cells; red denotes control (untreated) and blue
depicts cells after treatment with prednisolone 63µM for 96h (b.) CELSR2 expression
from clustered single cell populations of sensitive and resistant patients either without
treatment or after 96h prednisolone (c.) BCL2 expression from clustered single cell
populations of sensitive and resistant patients (d.) Bar plot depicting greater proportion of
sensitive leukemia cells (n=2,427 control cells; n= 924 treated cells) killed after treatment
with prednisolone for 96h compared to resistant patient (n= 686 control cells; n=759
treated cells; two proportion z-test p-value; **** = p <0.0001). (e.) Violin plot
representing kernel density of gene expression (individual points represent single cells) of
CELSR2 or (f.) BCL2 in CD19+ leukemia cell populations comparing prednisolone
treated to untreated cells in sensitive (n=2,427 control cells ; n= 924 treated cells) or
resistant patients (n= 686 control cells; n=759 treated cells; ** = p <0.01).

71

72

Figure 4-15. Chromatin status in glucocorticoid sensitive and resistant human
ALL cell lines, and perturbation of non-canonical WNT signaling by reduction of
CELSR2 expression
(a.) ATAC-seq for six human leukemia cell lines, three prednisolone sensitive and three
resistant cell lines depicting open chromatin in the region upstream of NR3C1 (n= 2
independent experiments). (b.) H3K27Ac data from ENCODE (black box) showing
lymphocyte regulatory region in GM12878 cell line (pink) (c.) RefSeq NR3C1 transcripts
(d.) ENCODE transcription factor binding sites for PAX5, NR3C1, TEAD4 and noncanonical Wnt effectors (NFATC1 and AP-1 [JUN and FOS]) (e.) Western blot and (f.)
Barplot (mean ± S.D.) depicting total cellular protein expression of signaling components
from planar cell polarity and Ca2+/NFAT non-canonical Wnt signaling protein CELSR2
knockdown vs. control cells with or without 10µM prednisolone treatment for 24hr. (g.)
Western blot and (h.) Barplot (mean ± S.D.) depicting cytoplasmic protein expression of
signaling components from planar cell polarity and Ca2+/NFAT non-canonical Wnt
signaling protein CELSR2 knockdown vs. control cells with or without 10µM
prednisolone treatment for 24hr.
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Figure 4-16. Perturbation of downstream non-canonical Wnt signaling leads to
decreased GR expression and glucocorticoid resistance
(a.) Representative western blot and (b.) Barplot (n= 3 independent experiments; mean ±
S.D.) depicting nuclear protein expression of signaling components from the planar cell
polarity and Ca2+/NFAT non-canonical Wnt signaling pathway, CELSR2 knockdown
(shCELSR2) vs. non-target control cells (NTC) with or without 10µM prednisolone
treatment for 24hr (two-tailed t-test p-values; * P < 0.05; ** P< 0.01***; P <0.001; ****
P<0.0001). (c.) Schematic representation of non-canonical Wnt signaling, depicting
proposed mechanism by which low CELSR2 expression leads to decreased expression of
the GR (right panel).
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significantly lower in CELSR2 knockdown cells compared to controls, in both
prednisolone treated (p=0.03) and untreated (p=0.0002) cells (Figure 4-15g-h).
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CHAPTER 5.

DISCUSSION*

Although there are several known genetic and epigenetic mechanisms of
glucocorticoid resistance in ALL, many leukemias are resistant for reasons that have
remained unknown. To assess the potential of agnostic genome-wide interrogation of
multiple forms of genomic and epigenetic variants to identify mechanisms of drug
resistance in human cancer, we assessed de novo prednisolone resistance in primary ALL
cells from newly diagnosed patients. The ex vivo sensitivity of ALL cells to
glucocorticoids is related to treatment outcome in ALL49,180 and was related to the
persistence of residual leukemia (MRD) in our patient cohort. We identified 655 interrelated genomic features associated with 463 genes and 48 miRNAs that discriminated
prednisolone sensitive and resistant ALL based on somatic variation in mRNA, miRNA,
CpG methylation, SNPs, CNAs or SNVs/Indels. Notably, 94% of the mRNAs
discriminating glucocorticoid sensitive and resistant ALL were statistically associated
with one or more of the significant miRNA, cis CpG-methylation sites, SNPs, CNAs or
SNVs/Indels within coding regions, indicating the interconnectivity of these genomic
features.
To assess the increased utility of interrogating multiple data types simultaneously,
we performed multivariable analysis using a forward selection method to generate a best
fit model using all feature types, yielding a model that explained ~47% of the variability
in prednisolone LC50 (93% before bias correction). This model contained 32 features: 4
mRNAs (CELSR2, FAM13A, NT5M and COBL) two of which are in our top 15 genes, 12
methylation probes (including BCL2), 2 miRNAs and 14 SNPs (Supplementary Table
1), supporting the use of multiple data types together in genomic studies of complex
phenotypes (e.g., drug resistance). Furthermore, many features not included in the
multivariable model were significantly related to other features in the model, providing
enhanced confidence in the genes identified. Gene-level integration of these six genomic
features identified 118 genes that were significantly associated with prednisolone
resistance by both the polygenomic and the TAP methods. Fifteen of these genes were
also significant in a genome-wide CRISPR-knockout screen, 14 of which have not been
previously associated with glucocorticoid resistance. The statistical probability of
capturing 15 genes in all three analyses by chance is extremely small (p= 8.2x10-79; see
Chapter 3).
To assess the robustness of our approach, we compared genes identified in the
current analyses with genes previously associated with glucocorticoid resistance in
ALL.19,58,59,61,63,65,68,75,77,85-87,100,107,109,110,113,114,116-118,120,123,136,137,139-141,196,197 This revealed
that 30 of 38 (79%) genes previously shown to confer glucocorticoid resistance in ALL
were directly identified by our agnostic, integrative polygenomic strategy. Some

-------------------*
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previously described genes such as CREBBP were not found directly, but genes known to
be associated with their function (CREB1) were found. When we included genes in the
same biological pathway, our method captured all 38 pathways previously shown to
confer glucocorticoid resistance in ALL.
Re-discovery of this large number of known mechanisms of resistance gives
confidence that many of the novel mechanisms are likely genuine, either as independent
mechanisms or as members of common pathways.
CELSR2 was the top novel gene downregulated in glucocorticoid resistant ALL
and decreasing CELSR2 expression recapitulated glucocorticoid resistance in human
leukemia cell lines. This also revealed genes that exhibited significantly altered
expression as a consequence of reducing CELSR2 expression, including markedly lower
expression of the GR and higher expression of anti-apoptotic BCL2 following
prednisolone treatment. We showed that co-administration of a BCL2 inhibitor
(venetoclax) mitigated glucocorticoid resistance due to low CELSR2 expression,
documenting greater synergy in ALL cell lines in which CELSR2 had been knocked
down and in primary leukemia cells with low CELSR2 expression. Low CELSR2
expression was documented in approximately half of glucocorticoid resistant ALL
patients (48%), suggesting that co-treatment with venetoclax could impact a large number
of patients and this combination may have even broader utility since other mechanisms of
glucocorticoid resistance involve lower GR expression or function.75 We also observed a
significant increase in survival in vivo in mice inoculated with CELSR2 knockdown ALL
cells when venetoclax (50 mg/kg) was given in combination with glucocorticoids (Figure
4-9c-d), consistent with our ex vivo findings of greater venetoclax sensitivity in primary
leukemia cells and human ALL cells lines with low CELSR2 expression (Figure 4-9a-b).
NetBID network analyses using interactome data generated in the independent
TARGET170 cohort, corroborated many of the genes and pathways that we found
significant, including CELSR2. This is consistent with CELSR2 and its network of
interacting genes acting as a master regulatory network influencing the sensitivity of
leukemia cells to prednisolone.
CELSR2 is a membrane-bound G-protein coupled receptor that alters gene
expression via non-canonical WNT signaling195 and HIPPO signaling,198 and is involved
in cell-cell interactions. Manipulation of CELSR2 in ALL cells led to alterations in
downstream non-canonical Wnt targets, increasing the expression of NFAT1 and cJun
and decreasing the phosphorylation of cJun at the total protein level,199 consistent with
the documented decreased activation of JNK via phosphorylation at Thr 183/Tyr 185.
Increasing the level of cJun represses transcription of the GR,200 as we observed in
primary ALL cells with low CELSR2 expression. We further documented significantly
lower nuclear levels of phosphorylated JNK and phosphorylated cJun, which forms a
heterodimer with FOS (AP1) to drive expression of NR3C1 (GR), consistent with lower
NR3C1 expression we observed in ALL with low CELSR2 expression. In future studies,
looking into targeting small molecules to CELSR2 or other associated non-canonical Wnt
pathway components could be a promising strategy to more directly target this pathway
in mitigating glucocorticoid resistance. Clinical trials have been developed looking at an

78

anti-ROR1(which is involved in non-canonical Wnt signaling and also an mRNA hit in
the polygenomic analysis) monoclonal antibody (cirmtuzumab) in B-cell malignancies
(NCT03088878), and a number of other Wnt targeted therapies have been developed that
are in various stages of clinical development.201
Taken together, we have shown that integration of agnostic multi-dimensional
somatic genome variants can identify discrete mechanisms of drug resistance in primary
leukemia cells, reliably rediscovering known mechanisms of resistance and revealing
mechanisms not previously reported. Our findings indicate that interrogating multiple
types of genomic variation improves the ability to discover mechanisms of resistance,
compared to interrogating only one type of genome variation. Applying this strategy, we
discovered a previously undescribed mechanism involving low expression of CELSR2 in
approximately 50% of glucocorticoid resistant ALL patients, causing lower expression of
GR and overexpression of BCL2, which can be mitigated by co-treatment with the BCL2inhibitor venetoclax. These findings represent a broad strategy for discovering genetic
and epigenetic mechanisms by which cancer cells develop resistance to chemotherapy,
and for revealing new therapeutic strategies to mitigate resistance.
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